Digchip : Database on electronics components
Electronics components database



Companies news of 2010-06-18 (page 4)

  • China North East Petroleum Holdings Ltd. Listing Compliance Plan Accepted by NYSE Amex
  • PASSUR Aerospace Announces $2.88 Million Contract with the Federal Aviation Administration...
  • China Sourcing Summit 2010 Attracts Global Sourcing Industry LeadersMore than 300 gather...
  • The Caldwell Partners International Announces Formal Alliance with Hawksmoor Search-...
  • West Coast Bank Supports the Forest Grove Public Arts CommissionPremier Sponsor of 'The...
  • MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men
  • New Research from Protiviti Finds Majority of Executives Experienced with Sarbanes-Oxley...
  • CVS Caremark and Walgreens Announce New PBM Network Pharmacy Agreement
  • Mylan Receives Approval for Generic Version of Zocor® Tablets
  • Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate for the...
  • SPX Announces Acquisition of Innovative Process Technologies and Systems Provider...
  • Charm Promotes Linna Li to CCTV Buying Platform Vice President
  • Charm Promotes Yihe Zhao to Market Research Vice President
  • Sinovac Schedules 2010 Annual Meeting of Shareholders
  • China Finance Online Hosted Shanghai-Themed Investment Forum
  • New Energy Systems Group Creates Audit, Compensation and Nominating Committees
  • TreeHouse Foods Announces Webcast of Second Quarter 2010 Earnings Results Conference Call
  • Alliant Energy Requests Proposals for Sale of Industrial Energy Applications, Inc.
  • Rentrak Announces Top Ten Movies-on-Demand Titles Week Ending June 13, 2010
  • MSC Industrial Direct Co., Inc. to Broadcast Review of Third Quarter 2010 Results Over the...
  • MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men
  • MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men
  • Rentrak to Present at the Advanced Advertising 2.0 Conference Presented by Broadcasting &...
  • Dollar Thrifty Automotive Group Completes New $300 Million Asset Backed Financing
  • Chemspec International Limited Files 2009 Annual Report on Form 20-F
  • China Unicom Announces Filing of Form 20-F with SEC
  • Logo Announces Winners for This Year's 'NewNowNext Awards''Glee's' Lea Michele, Johnny...
  • STMicroelectronics and Tsinghua University Announce Long-Term Strategic R&D Partnership
  • National Technical Systems Declares Special Dividend
  • CNOOC Ltd. Completes Acquisition of Stake in Block 15/34



    China North East Petroleum Holdings Ltd. Listing Compliance Plan Accepted by NYSE Amex

    HARBIN, China and NEW YORK, June 18 /PRNewswire-Asia-FirstCall/ -- China North East Petroleum Holdings Ltd. (the "Company" or "NEP") (NYSE Amex: NEP), a leading independent oil producing and oilfield services company in Northern China, today reported that on June 15, 2010, China North East Petroleum Holdings Limited (the "Company") received notice from NYSE Amex LLC ("AMEX") that AMEX has accepted the Company's compliance plan. AMEX also granted the Company an extension until July 14, 2010 to regain compliance with AMEX's continued listing standards.

    As previously disclosed, the Company went out of compliance with AMEX's continuing listing criteria set forth in Sections 134 and 1101 of the NYSE Amex LLC Company Guide (the "Company Guide") when it failed to file timely its annual report on Form 10-K for the fiscal year ended December 31, 2009 and Form 10-Q for the quarter ended March 31, 2010.

    In response, AMEX afforded the Company the opportunity to submit a plan of compliance. On April 29, 2010 and, as supplemented on June 6, 2010, the Company submitted a plan to AMEX that set forth the actions it had taken and would take to bring the Company into compliance with the standards set forth in Sections 134 and 1101 of the Company Guide. Now, AMEX has determined that, in accordance with Section 1009 of the Company Guide, the Company's compliance plan makes a reasonable demonstration of the Company's ability to regain compliance with AMEX's continued listing standards.

    The Company will be subject to periodic review by AMEX staff during the extension period. Failure to make progress consistent with the compliance plan or to regain compliance with the continued listing standards by the end of the extension period could result in a delisting from AMEX.

    Mr. Jingfu Li, the Company's acting CEO commented, "We are pleased the Exchange is comfortable with our efforts to regain compliance with its continued listing standards. The Company is looking forward to the results of the current accounting efforts and filing our delayed 10-K and 10-Q as soon as possible"

    ABOUT CHINA NORTH EAST PETROLEUM

    China North East Petroleum Holdings Limited is an independent oil company that engages in the production of crude oil in Northern China. The Company is a pioneer in China's private oil exploration and production industry, and the first Chinese non-state-owned oil company trading on the NYSE Amex.

    The Company has a guaranteed arrangement with the PetroChina to sell its produced crude oil for use in the China marketplace. The Company currently operates four oilfields in Northern China. The Company also recently added an oil service subsidiary through its acquisition of Song Yuan Tiancheng Drilling Engineering Co. Ltd. ("Tiancheng"). For more information about the Company, please visit http://www.cnepetroleum.com/ .

    Statements in this press release, including but not limited to those relating to the Company's or management's intentions, beliefs, expectations, hopes, projections, assessment of risks, estimations, plans or predictions for the future, including the impact of the restatement, timing of filings with the SEC and other statements that are not historical facts are forward-looking statements that are based on current expectations. Although the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that these expectations will prove correct. Important factors that could cause actual results to differ materially from those in the forward-looking statements include delays and uncertainties that may be encountered in connection with the restatement, final audits and reviews by the Company and its auditors, and other risks described in the Company's annual report on Form 10-K for the year ended December 31, 2008 and its other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Investors should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of the particular statement and the Company undertakes no duty to update any forward-looking statement.

    For more information, please contact: Bill Zima ICR, Inc. Tel: +1-203-682-8200

    China North East Petroleum Holdings Limited

    CONTACT: Bill Zima of ICR, Inc., +1-203-682-8200, for NEP

    Web Site: http://www.cnepetroleum.com/




    PASSUR Aerospace Announces $2.88 Million Contract with the Federal Aviation Administration for Airspace Security Applications

    STAMFORD, Conn., June 18 /PRNewswire-FirstCall/ -- PASSUR Aerospace, Inc. (BULLETIN BOARD: PSSR) announced today that it has been awarded a $2.88 million contract with the Federal Aviation Administration (FAA) for a 1-year pilot program to provide access to Air Traffic Control and Aviation Security related products in support of the FAA's joint role with the Transportation Security Administration (TSA).

    "We're very proud to partner with the FAA and the TSA in support of the multi-agency mission of airspace security," said Jim Barry, PASSUR Aerospace's President and CEO. "And we're equally proud of our team's ability to deliver the robust, reliable, and sophisticated technology and services that are required for this project."

    "We have invested extensively in our surveillance, data acquisition, flight and airspace analytics, real-time decision support, and business intelligence capabilities," said G. S. Beckwith Gilbert, PASSUR Aerospace's Chairman of the Board. "It is gratifying that our solutions can be applied to help the Government deliver on its security mission."

    PASSUR Aerospace is the sole provider of all products and services to be performed under this contract. Specific solutions will be delivered through the FAA's ADAPT (Automatic Detection and Processing Terminal) System, and will include both data feeds as well as end-user software applications. The PASSUR solutions derive from several core PASSUR capabilities, including its national network of surveillance systems, which includes extended coverage of critical airspace corridors; its integrated database of live and historical flight and airspace information; flight behavior algorithms; flight and airspace visualization technology; and collaborative information dashboards for instant alerts and decision support, as well as the ability to immediately share information and coordinate action.

    About PASSUR Aerospace, Inc.

    PASSUR Aerospace, Inc. is a business intelligence company which provides its customers predictive analytics built on proprietary algorithms and on the concurrent integration and simultaneous mining of multiple databases. We believe we provide the industry standard in business intelligence dashboards and predictive analytics for aviation organizations. PASSUR serves most major airlines (including 6 of the top 7 North American airlines, as well as the top five hub airlines), over 50 airport customers (including 10 of the top 15 North American airports), and more than 200 corporate aviation customers. PASSUR's system is driven by its proprietary, patented, business intelligence software which is powered by a unique North American network of 140 passive radars, company owned, including one located at each of the top 35 U.S. airports. Other PASSURs are located in Europe and Asia. Flight tracks are updated every 4.6 seconds, thereby providing a system which is user-friendly and useful for decision-making.

    Visit PASSUR Aerospace's web site at http://www.passur.com/ for updated products, solutions, and PASSUR news.

    The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those related to customer needs, budgetary constraints, competitive pressures, the success of airline trials, the profitable use of the Company's owned PASSURs located at major airports, the Company's maintenance of above average quality of its product and services, as well as potential regulatory changes. Further information regarding factors that could affect the Company's results is contained in the Company's SEC filings, including the October 31, 2009 Form 10-K and April 30, 2010 Form 10-Q.

    Contact: Ron Dunsky (203) 622-4086 rondunsky@passur.com

    PASSUR Aerospace, Inc.

    CONTACT: Ron Dunsky, +1-203-622-4086, rondunsky@passur.com

    Web Site: http://www.passur.com/




    China Sourcing Summit 2010 Attracts Global Sourcing Industry LeadersMore than 300 gather to discuss development of Chinese outsourcing market

    HOUSTON, June 18 /PRNewswire/ -- TPI, the largest sourcing data and advisory firm in the world and a unit of Information Services Group, Inc. (ISG) , an industry-leading information-based services company, today announced that the China Sourcing Summit 2010, the country's first national conference aimed at promoting development of the domestic outsourcing industry, attracted more than 300 participants, including services buyers, providers and advisors as well as key officials from the government.

    The event, which was organized by TPI, the China Council for International Investment Promotion (CCIIP) and the Hangzhou Municipal Government and sponsored by the Ministry of Commerce (MOC) and other government ministries, brought global leaders and local experts together to discuss the evolution of China's sourcing market and the impact its fast-growing economy and global delivery capability are having on the industry worldwide.

    The theme of the event, which covered topics such as sourcing governance, data privacy, intellectual property protection and government regulation, was "Survival of the Fittest." Speakers included executives with experience at Disney, DuPont and high-tech leader Symantec, who discussed strategies for accelerating the growth of outsourcing by international firms. Participants also had the opportunity to tour the facilities of local service providers and learn from the experiences of multinational buyers already working in China.

    "The sourcing industry in China is changing dramatically, and that has created opportunities for the fittest companies to prosper," said Michael Rehkopf, Partner and Director, North Asia, TPI. "At the China Sourcing Summit, we not only identified the challenges for clients and service providers wanting to capitalize on these opportunities, we also shared ideas on how they can overcome them."

    Since launching in China last year, TPI has been working with the MOC and CCIIP to accelerate development of the sourcing market, including the establishment of protocols designed to make the country more attractive to multinational corporations seeking to diversify their global footprints.

    "The emergence of China as a global sourcing destination is an exciting and important development for our industry," said Michael P. Connors, Chairman & CEO, ISG and TPI, who hosted the launch of the China Sourcing Summit 2010. "The success of this event proves that clients and services providers from around the world want to do business here. With our partners at the MOC and CCIIP, TPI can help them do that."

    About TPI

    TPI, a unit of Information Services Group, Inc. (ISG) , is the founder and innovator of the sourcing advisory industry, and the largest sourcing data and advisory firm in the world. We are expert at a broad range of business support functions and related research methodologies. Utilizing deep functional domain expertise and extensive practical experience, our accomplished industry experts collaborate with organizations to help them advance their business operations through the best combination of business process improvement, shared services, outsourcing and offshoring. In 2010, TPI ranked no. 1 in the International Association of Outsourcing Professionals Global Outsourcing 100: World's Best Outsourcing Advisors. For additional information, visit http://www.tpi.net/.

    About Information Services Group, Inc.

    Information Services Group, Inc. (ISG) was founded in 2006 to build an industry-leading, high-growth, information-based services company by acquiring and growing businesses in advisory services, including strategy, implementation and management, and market information, including market measurement, analytics and related product and services. In November 2007, the company acquired TPI, the largest sourcing data and advisory firm in the world. Based in Stamford, Conn., ISG has a proven leadership team with global experience in information-based services and a track record of creating significant value for shareowners, clients and employees. For more, visit http://www.informationsg.com/.

    TPI

    CONTACT: Andrew Park, TPI, +1-919-259-9252, andrew.park@tpi.net; or
    Rhena Wallace, Cohn & Wolfe for TPI, +1-212-798-9832,
    rhena.wallace@cohnwolfe.com

    Web Site: http://www.tpi.net/




    The Caldwell Partners International Announces Formal Alliance with Hawksmoor Search- Strategic London-based alliance further strengthens firm's insurance industry capabilities -

    TORONTO, June 18 /PRNewswire-FirstCall/ -- Retained executive search firm The Caldwell Partners International Inc. (TSX: CWL) today announced an exclusive alliance with Hawksmoor Search, with both firms partnering to better serve clients in the insurance industry.

    Based in London, Hawksmoor Search is a retained executive search boutique specializing in board and senior management recruitment for clients in the insurance and reinsurance markets worldwide. The firm was recently launched by Matthew Andrews, an executive search consultant serving the insurance industry since 1987, most recently from CTPartners.

    With this alliance, the combined insurance practice of Hawksmoor Search and The Caldwell Partners now has four seasoned partners covering the spectrum of life and P&C, direct and reinsurance, underwriters and brokers as well as functional and technical specialties.

    "Matthew has a close understanding of the issues facing leaders in all sectors of the global insurance industry," said Mike Corey, leader of Caldwell's insurance practice in North America. "In addition to his numerous CEO and board level appointments, his background in insurance gives him unique insight into senior underwriting and broking roles.

    "Coming on the heels of our hiring of Peter Reed, this move demonstrates our commitment to building the best dedicated insurance team in the industry, serving clients in North America, Bermuda and Europe," Corey continued.

    "The alliance between Hawksmoor and Caldwell Partners is based on mutual respect, shared values and a successful track record," said Matthew Andrews, Director of Hawksmoor Search. "Peter Reed and I have worked together for more than 10 years and can point to a long list of assignments executed seamlessly in North America and Europe."

    "Partnering with Hawksmoor allows us to strategically expand a key practice area, and put a best-in-class team in front of our clients," said John N. Wallace, President and Chief Executive Officer. "We have a dynamic, quality-focused team of 31 partners in 10 cities across North America, and now we also have a strategic presence in London."

    About The Caldwell Partners

    Founded in 1970, The Caldwell Partners International Inc is a retained executive search firm specializing in recruiting "C-class" executives (chief executive, chief financial, chief information officers, as well as other senior executives) and their direct reports. With offices and partners in Vancouver, San Francisco, Los Angeles, Dallas, Calgary, Chicago, Atlanta, Toronto, Stamford, and New York City, the firm takes pride in delivering an unmatched level of service and expertise to its clients.

    The Caldwell Partners' Common shares are listed on The Toronto Stock Exchange (TSX: CWL). Please visit our website at http://www.caldwellpartners.com/ for further information.

    About Hawksmoor Search

    Hawksmoor Search is a London-based specialist executive search boutique operating at the board and senior management level. For over twenty years the members of our team have been conducting successful search assignments in the insurance and reinsurance markets worldwide. We identify and deliver the most talented senior executives in the insurance industry.

    Please visit our website at http://www.hawksmoorsearch.com/ for further information.

    Forward-Looking Statements

    Forward-looking statements in this document are based on current expectations that are subject to significant risks and uncertainties. Actual results might differ materially due to various factors such as the competitive nature of the executive search industry, the ability of the company to execute its growth strategies, the performance of the Canadian domestic and international economies, and the company's ability to retain key personnel. The Caldwell Partners assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

    The Caldwell Partners International Inc.

    CONTACT: Caroline Lomot, The Caldwell Partners International,
    clomot@caldwellpartners.com, +1.516.830.3535




    West Coast Bank Supports the Forest Grove Public Arts CommissionPremier Sponsor of 'The Main Course,' Forest Grove's Annual Food and Wine Celebration

    FOREST GROVE, Ore., June 18 /PRNewswire-FirstCall/ -- West Coast Bank is a premier sponsor for the fifth year of "The Main Course," a celebration of Northwest food and wine held on Main Street in Forest Grove, Oregon's historic downtown section. The event supports the Forest Grove Public Arts Commission and features 13 local wineries and a four-course meal from Stecchino's, Forest Grove's newest restaurant. Local music will play throughout the wine tasting and dinner, which will be held Saturday, July 10th, from 5:30 PM to 10 PM.

    West Coast Bank Forest Grove Branch Manager Michelle Gilbertson, who is also a Main Course committee member, said, "It's a pleasure to participate in a classy event like The Main Course which promotes local businesses and funds a worthy cause. It's all part of West Coast Bank's commitment to the communities we serve."

    "The Main Course" is a non-profit event being coordinated through the Forest Grove Foundation. For more information or to purchase tickets, see http://www.maincoursedinner.com/.

    West Coast Bancorp is a Northwest bank holding company with $2.7 billion in assets, operating 65 locations in Oregon and Washington. The Company combines the sophisticated products and expertise of larger banks with the local decision making, market knowledge and customer service of a community bank. For more information, visit the Company's web site at http://www.wcb.com/.

    West Coast Bank

    CONTACT: Dave Hansen, Regional President of West Coast Bank,
    +1-503-603-8040, hansend@wcb.com

    Web Site: http://www.wcb.com/




    MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men

    NATICK, Mass. and NICE, France, June 18 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced results from a sub-analysis of the MADIT-CRT trial data that showed women received a greater clinical benefit from its cardiac resynchronization therapy defibrillators (CRT-Ds) than men. The results were presented during the 17th Cardiostim World Congress by Jonathan Steinberg, M.D., Chief of Cardiology and Director of the Al-Sabah Arrythmia Institute, St. Luke's-Roosevelt Hospital Center, New York.

    The sub-analysis demonstrated that both men and women experienced significant benefit from cardiac resynchronization therapy. However, women experienced a 70 percent reduction in heart failure events compared to a 35 percent reduction for men. Additional analysis demonstrated that women with asymptomatic or mild heart failure experienced a 72 percent reduction in all-cause mortality.

    "There are a number of factors that may explain why women experienced a greater benefit than men," said Arthur Moss, M.D., Professor of Medicine at the University of Rochester Medical Center and Principal Investigator of the MADIT-CRT trial. "CRT-D therapy is designed to improve the heart's overall pumping ability and women are more likely than men to have non-ischemic heart disease, which typically affects the entire heart rather than a single region and can lead to reduced pumping strength, abnormal heart rhythms and disturbances in the heart's electrical system. Men are more likely to have ischemic heart disease, also known as coronary artery disease, which often leads to a more localized impact on the heart."

    "These findings are noteworthy because CRT-D therapy has historically been underutilized in women compared to men with the same level of heart disease," said Kenneth Stein, M.D., Chief Medical Officer, CRM, for Boston Scientific's Cardiology, Rhythm and Vascular Group. "Boston Scientific believes that all patients should have equal access to high-quality cardiovascular care regardless of gender. We believe these findings will help reduce treatment disparities between men and women."

    MADIT-CRT is the world's largest randomized CRT-D study of New York Heart Association (NYHA) Class I and II patients(1), with more than 1,800 patients enrolled at 110 centers worldwide. Results of the MADIT-CRT trial were published in the October 2009 issue of the New England Journal of Medicine. Boston Scientific currently has an application under review with the U.S. Food and Drug Administration for the expansion of its CRT-D indication to include high-risk(2) NYHA Class I and II patients with Left Bundle Branch Block.

    Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.

    (1) The NYHA clinical classifications of heart failure rank patients as Class I-II-III-IV, according to the degree of symptoms or functional limits, from asymptomatic to bed ridden. MADIT-CRT patients are asymptomatic or mildly symptomatic, NYHA Class I (ischemic) and Class II (ischemic and non-ischemic).

    (2) High-risk is defined as QRS width >/= 130 milliseconds with Left Ventricular Ejection Fraction

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, clinical outcomes, regulatory approval of our products, and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

    Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT: Paul Donovan 508-650-8541 (office) 508-667-5165 (mobile) Media Relations Boston Scientific Corporation David Knutson 651-582-6574 (office) 651-260-8288 (mobile) Media Relations Boston Scientific Corporation Larry Neumann 508-650-8696 (office) Investor Relations Boston Scientific Corporation

    Boston Scientific Corporation

    CONTACT: Media Relations: Paul Donovan, +1-508-650-8541 (office),
    +1-508-667-5165 (mobile), or David Knutson, +1-651-582-6574 (office),
    +1-651-260-8288 (mobile), Investor Relations: Larry Neumann, +1-508-650-8696
    (office), all of Boston Scientific Corporation

    Web Site: http://www.bostonscientific.com/




    New Research from Protiviti Finds Majority of Executives Experienced with Sarbanes-Oxley Compliance Believe Benefits Outweigh the CostsNew SOX survey uncovers spending trends, attitudes, outlooks and more

    MENLO PARK, Calif., June 18 /PRNewswire/ -- Attitudes toward Sarbanes-Oxley (SOX) compliance and spending evolve significantly the longer a company is involved with the compliance process, according to new research from Protiviti (http://www.protiviti.com/), a global business consulting and internal audit firm. Protiviti's 2010 Sarbanes-Oxley Compliance Survey (http://www.protiviti.com/soxsurvey) reports that 70 percent of surveyed executives in year four or beyond of their SOX compliance indicated that the benefits of compliance outweighed its costs, compared to only 39 percent of surveyed executives in their first-year compliance. This finding is largely attributable to the significant decline in compliance costs as companies gain experience in applying Section 404 of SOX.

    (Logo: http://photos.prnewswire.com/prnh/20090115/AQTH541LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20090115/AQTH541LOGO)

    Protiviti's 2010 Sarbanes-Oxley Compliance Survey - which includes feedback from more than 400 U.S. executives and professionals across numerous industry sectors - assesses the current state of SOX compliance, related costs, associated benefits and value, as well as how to achieve a desired state of verifiable compliance and sustainability.

    Business leaders surveyed report, on average, a 50 percent reduction in compliance costs among companies in their fourth year and beyond. In addition, most survey participants - 87 percent - believe SOX compliance offers some benefit beyond simply fulfilling SEC regulations.

    "Organizations have come a long way in the eight years since SOX was first enacted," said Bob Hirth, Protiviti executive vice president and leader of the firm's global internal audit and financial controls practice. "What was once a compliance 'burden' for many companies, managed in an ad hoc or project manner and at a high cost, has evolved into something broader than its original objective. While not everyone agrees with all of its requirements, respondents in our survey certainly recognize that SOX has triggered benefits including increased efficiency and effectiveness of processes and operations, greater understanding of control design, and operating effectiveness."

    "Together with the reduction in compliance costs that more companies are achieving, these benefits have resulted in new, more positive views toward SOX," Hirth added.

    Other key findings from Protiviti's SOX survey include: -- Nearly 80 percent of all organizations participating in the survey said they automate less than half of their key controls, indicating an opportunity to increase efficiency. However, most respondents said their organizations had minimal plans for additional automation. -- More than 70 percent of respondents indicated a high dependency on spreadsheets, making it the top inefficiency negatively impacting SOX compliance efforts. -- Thirty-five percent of respondents plan to use continuous monitoring tools or techniques this year as a key part of their SOX compliance strategy. -- Close to half of respondents perform all of their SOX compliance work in-house. Outsourcing of SOX work is typically highest during the initial compliance years.

    "It's very important for organizations to continuously examine the state of their compliance processes to ensure they are cost-effective and add value to the organization," said Jim DeLoach, a Protiviti managing director and the firm's senior SOX practice leader as well as a key survey architect. "Companies can achieve significant benefits from SOX beyond compliance, but to do so they need to view their efforts as an ongoing activity that should mature and improve over time. That emphasis would lead them to evaluate the upstream business processes impacting financial reporting. Streamlining and automating those processes would lead to more cost-effective internal controls which, in turn, lead to more cost-effective compliance."

    Protiviti's 2010 Sarbanes-Oxley Compliance Survey gathered insights from C-suite executives, corporate Sarbanes-Oxley leaders and audit professionals at companies with gross annual revenues ranging from less than $100 million to more than $20 billion. Sixty-eight percent of respondents work for companies in or beyond their fourth year of SOX compliance and 70 percent are from large or accelerated filers.

    The 2010 Sarbanes-Oxley Compliance Survey was conducted in the first quarter of 2010 to assess the strategies and tactics companies have employed to derive value from the SOX compliance process. A complimentary copy of the survey is available at: http://www.protiviti.com/soxsurvey.

    About Protiviti

    Protiviti is a global business consulting and internal audit firm composed of experts specializing in risk, advisory and transaction services. The firm helps solve problems in finance and transactions, operations, technology, litigation, governance, risk, and compliance. Protiviti's highly trained, results-oriented professionals provide a unique perspective on a wide range of critical business issues for clients in the Americas, Asia-Pacific, Europe and the Middle East.

    Protiviti has more than 60 locations worldwide and is a wholly owned subsidiary of Robert Half International Inc. . Founded in 1948, Robert Half International is a member of the S&P 500 index.

    Protiviti is not licensed or registered as a public accounting firm and does not issue opinions on financial statements or offer attestation services.

    Photo: http://www.newscom.com/cgi-bin/prnh/20090115/AQTH541LOGO
    AP Archive: http://photoarchive.ap.org/
    PRN Photo Desk, photodesk@prnewswire.com
    http://photos.prnewswire.com/prnh/20090115/AQTH541LOGO Protiviti

    CONTACT: Kathy Keller of Protiviti, +1-650-234-6252,
    kathy.keller@protiviti.com

    Web Site: http://www.protiviti.com/




    CVS Caremark and Walgreens Announce New PBM Network Pharmacy Agreement

    WOONSOCKET, R.I., and DEERFIELD, Ill., June 18 /PRNewswire-FirstCall/ -- CVS Caremark Corporation and Walgreens today announced that the companies have reached an agreement on terms under which Walgreens will continue participating in the CVS Caremark pharmacy benefit management (PBM) national retail network for existing, new or renewal plans. The companies are not disclosing the financial terms of the new contract.

    (Logo: http://photos.prnewswire.com/prnh/20100618/NE23241LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20100618/NE23241LOGO )

    "We are very pleased with the outcome of this mutual, multi-year agreement that meets our business objectives," said Walgreens Executive Vice President of Pharmacy, Kermit Crawford. "The agreement makes good business sense, provides the framework we need to operate our business going forward, and assures choice and convenience for the many consumers who look to us for quality pharmacy care. The agreement is good for our patients, pharmacists and shareholders, and will allow us to continue to meet the needs of our customers across the country through the CVS Caremark network."

    Per Lofberg, President of CVS Caremark's pharmacy benefit management business, said, "We are pleased to have reached a mutually agreeable solution together with Walgreens that is consistent with our top priority to provide convenient access to affordable high-quality pharmacy health care. This new contract enables Walgreens to continue participating in CVS Caremark's PBM national pharmacy network, provides enhanced network stability, eliminates any current or long-term disruption for our clients or their members and allows us to continue to fulfill our obligation to deliver cost-effective pharmacy benefits for our clients."

    With the continuing participation of Walgreens, the CVS Caremark national pharmacy network will have more than 64,000 participating pharmacies, including neighborhood independent pharmacies, chain pharmacies, and those located in supermarkets and other major retailers.

    About CVS Caremark:

    CVS Caremark is the largest pharmacy health care provider in the United States. Through our integrated offerings across the entire spectrum of pharmacy care, we are uniquely positioned to provide greater access to engage plan members in behaviors that improve their health, and to lower overall health care costs for health plans, plan sponsors and their members. CVS Caremark is a market leader in mail order pharmacy, retail pharmacy, specialty pharmacy, and retail clinics, and is a leading provider of Medicare Part D Prescription Drug Plans. As one of the country's largest pharmacy benefits managers (PBMs), we provide access to a network of more than 64,000 pharmacies, including over 7,000 CVS/pharmacy® stores that provide unparalleled service and capabilities. Our clinical expertise includes one of the industry's most comprehensive disease management programs. General information about CVS Caremark is available through the Company's website at http://info.cvscaremark.com/.

    CVS Caremark Forward-looking statements:

    This press release contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2009 and under the caption "Cautionary Statement Concerning Forward Looking Statements" in our Quarterly Report on Form 10Q for the quarter ended March 31, 2010.

    About Walgreens:

    Walgreens (http://www.walgreens.com/) is the nation's largest drugstore chain with fiscal 2009 sales of $63 billion. The company operates 7,522 drugstores in all 50 states, the District of Columbia and Puerto Rico. Walgreens provides the most convenient access to consumer goods and services and cost-effective pharmacy, health and wellness services in America through its retail drugstores and Walgreens Health and Wellness division. The division includes Take Care Health Systems, the largest and most comprehensive manager of worksite health and wellness centers and in-store convenient care clinics, with more than 700 locations throughout the country.

    Walgreens Forward-looking statements:

    This news release may contain forward-looking statements that involve risks and uncertainties. The following factors could cause results to differ materially from management expectations as projected in such forward-looking statements: seasonal variations, competition, risks of new business areas, the availability and cost of real estate and construction, and changes in federal or state legislation or regulations. Investors are referred to the "Cautionary Note Regarding Forward-Looking Statements" in the Company's most recent Form 10-K, which Note is incorporated into this news release by reference.

    Media Contact: Media Contact: Eileen Howard Dunn Michael Polzin CVS Caremark Walgreen Co. Senior Vice President Divisional Vice President Corporate Communications Corporate Communications (401) 770-4561 (847) 914 - 2920 Investor Contact: Investor Contact: Nancy Christal Rick Hans, CFA CVS Caremark Walgreen Co. Senior Vice President Divisional Vice President Investor Relations Investor Relations and Finance (914) 722-4704 (847) 914-2385

    Photo: http://www.newscom.com/cgi-bin/prnh/20100618/NE23241LOGO
    PRN Photo Desk, photodesk@prnewswire.com
    http://photos.prnewswire.com/prnh/20100618/NE23241LOGO CVS Caremark Corporation; Walgreens

    CONTACT: Media, Eileen Howard Dunn, Senior Vice President, Corporate
    Communications, +1-401-770-4561, or Investors, Nancy Christal, Senior Vice
    President, Investor Relations, +1-914-722-4704, both of CVS Caremark; or
    Media, Michael Polzin, Divisional Vice President, Corporate Communications,
    +1-847-914-2920, or Investors, Rick Hans, CFA, Divisional Vice President,
    Investor Relations and Finance, +1-847-914-2385, both of Walgreen Co.

    Web Site: http://info.cvscaremark.com/




    Mylan Receives Approval for Generic Version of Zocor® Tablets

    PITTSBURGH, June 18 /PRNewswire-FirstCall/ -- Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg, 40 mg and 80 mg, the generic version of Merck & Co.'s Zocor® Tablets, a treatment for high cholesterol. The product will be distributed by Mylan Pharmaceuticals Inc.

    Simvastatin Tablets had U.S. sales of approximately $361 million for the 12 months ending March 31, 2010, according to IMS Health.

    Currently, Mylan has 137 ANDAs pending FDA approval representing $94.8 billion in annual brand sales, according to IMS Health. Forty of these pending ANDAs are potential first-to-file opportunities, representing $21 billion in annual brand sales, for the 12 months ending Dec. 31, 2009 according to IMS Health.

    Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit http://www.mylan.com/.

    Mylan Inc.

    CONTACT: Michael Laffin (Media), +1-724-514-1968, or Kris King
    (Investors), +1-724-514-1813, both of Mylan Inc.

    Web Site: http://www.mylan.com/




    Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of RheumatologyNew Data from Five Clinical Studies Reinforce RDEA594's Robust Efficacy and Encouraging Safety Profile

    ROME, June 18 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. today announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by increasing the excretion of uric acid in order to bring the body's levels of uric acid into a normal range.

    Highlights of the new data being presented at EULAR include: -- Updated results from a Phase 2b monotherapy study of RDEA594 in 123 gout patients demonstrating a 60% response rate at the highest dose tested. -- Interim results from an ongoing Phase 1b study examining the pharmacokinetics and pharmacodynamics of RDEA594 and allopurinol separately and in combination that demonstrate a 100% response rate in patients receiving two different doses of RDEA594 combined with allopurinol. -- Results from multiple studies indicating that the efficacy of RDEA594 is not diminished in patients with mild-to-moderate renal impairment. -- Safety results from five clinical studies indicating that RDEA594 is well tolerated alone or in combination with allopurinol or febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen and Menarini), with no occurrence of drug-related serious adverse events or dose-related side effects.

    "We are pleased to see the very strong and consistent efficacy data from these studies," said Barry D. Quart, PharmD, President and Chief Executive Officer of Ardea Biosciences. "The interim results from our ongoing Phase 1b study of RDEA594 in combination with allopurinol and our completed proof-of-concept study with febuxostat indicate we can achieve up to 80% mean reductions of uric acid levels when combined with currently marketed agents for the treatment of gout. These combinations would be among the most potent uric acid lowering treatments available."

    "RDEA594 has demonstrated a very consistent efficacy and safety profile," stated Dr. Fernando Perez-Ruiz, Assistant Head of the Rheumatology Division, Hospital de Cruces, Vizcaya, Spain. "New data from the studies presented at EULAR not only position the drug for Phase 3 studies, but further demonstrate RDEA594's potential to be an important new therapy to treat the millions of gout patients who are currently untreated or under-treated and continue to experience painful and debilitating flares due to the inadequate hypouricemic effect of approved therapies."

    Updated Results from Phase 2b Monotherapy Study

    Updated results from Ardea's Phase 2b study of RDEA594 given as monotherapy are being presented in an oral presentation at EULAR. One hundred twenty-three patients with gout and hyperuricemia were randomized and dosed in this 28-day, double-blind, placebo-controlled, dose-escalation study. The primary endpoint of this study, which tested three doses of RDEA594 (200 mg, 400 mg and 600 mg) given once daily was the proportion of patients who achieved a response, defined as a reduction of uric acid in the blood to below 6 mg/dL after 4 weeks of treatment, compared to placebo. The primary endpoint of the study was achieved, and serum uric acid levels decreased and response rates increased in a dose-related manner. The response rates on placebo, 200 mg RDEA594, 400 mg RDEA594 and 600 mg RDEA594 were 0%, 13%, 42% and 60%, respectively. The response rates in both the 400 mg and 600 mg dose groups were highly clinically and statistically significant. For patients with baseline uric acid levels less than 10 mg/dL, who represent the majority of gout patients in clinical practice, response rates were 57% and 75% in the 400 mg and 600 mg dose groups, respectively.

    Updated Efficacy Results of Phase 2b Monotherapy Study of RDEA594 in the Treatment of Hyperuricemia in Gout Patients Treatment Groups RDEA594 RDEA594 RDEA594 600 mg qd 400 mg qd 200 mg qd Placebo Response Rate 60% 42% 13% 0% (Primary Endpoint) (n = 32) (n = 33) (n = 31) (n = 27) p Value versus Placebo < 0.0001 0.0001 NS Response Rate in Pts. with Baseline Serum Urate < 10 mg/dL 75% 57% 21% 0% (n = 12) (n = 14) (n = 18) (n = 14) p Value versus Placebo 0.0001 0.0004 NS NS = not statistically significant

    The updated response rates from the results of this study are higher than the preliminary, top-line results reported on March 31, 2010. This difference is due to a difference in the method used to measure the levels of uric acid in the blood. The preliminary, top-line results were generated using an indirect assay method (UV), while the updated response data were generated using a direct, more precise assay method (LC-MS/MS).

    Initial Combination Therapy Results

    In addition to an ongoing Phase 2b study examining the combination of RDEA594 and allopurinol, Ardea is currently conducting a Phase 1b, open-label clinical pharmacology study examining the pharmacokinetics and pharmacodynamics (PK/PD) of this combination. Interim results of this PK/PD study and final results from a previously reported Phase 2a study of the combination of RDEA594 and allopurinol are being presented at EULAR.

    Allopurinol is the most widely prescribed drug currently available to treat gout patients. However, recent controlled studies have shown that less than 50% of patients reach target uric acid reduction (sUA less than 6 mg/dL) on a standard allopurinol dose of 300 mg per day. RDEA594 lowers excessive uric acid levels (the underlying cause of gout) by increasing uric acid excretion, while allopurinol decreases its production. Ardea believes that the combination of RDEA594 with allopurinol may provide an important treatment option for the significant portion of gout patients who do not achieve adequate response to allopurinol treatment alone by potentially enabling them to further reduce their uric acid levels to within the normal range.

    In the ongoing PK/PD study, patients receive a 300 mg dose of allopurinol alone for one week, then allopurinol plus RDEA594 at a dose of either 600 mg or 400 mg for one week, then RDEA594 at the same dose alone for one week. Currently, 11 of approximately 20 patients planned have completed dosing in the study (mean baseline sUA = 9.2 mg/dL).

    Consistent with the combination results from a previously reported Phase 2a study, interim results from this PK/PD study indicate that combining RDEA594 with allopurinol produces greater reductions in uric acid levels than observed with either agent alone. As illustrated in the table below, 100% of patients in the PK/PD study who have completed dosing on either 600 mg or 400 mg of RDEA594 plus allopurinol reached target serum uric acid levels of below 6 mg/dL. Furthermore, at the RDEA594 600 mg combination dose, all patients who have completed dosing achieved a reduction to below 5 mg/dL sUA. The combination has been well tolerated, with no serious adverse events, no discontinuations, and no clinically relevant changes in any laboratory parameter, except the desired reduction in serum urate.

    PK/PD Study Interim Results sUA Response - % of Patients Treatment Groups Allopurinol 300 mg RDEA594 400 mg RDEA594 600 mg Alone + Allopurinol 300 mg + Allopurinol 300 mg (n = 11) (n = 6) (n = 5) < 6 mg/dL 27% 100% 100% < 5 mg/dL 9% 67% 100% < 4 mg/dL 0% 0% 60%

    Ardea is also studying the use of RDEA594 in combination with febuxostat, which, like allopurinol works by decreasing uric acid production. Data from a proof-of-concept study examining the combination of RDEA594 and febuxostat are being presented at EULAR.

    In this randomized, placebo-controlled study in healthy volunteers with serum uric acid levels generally above 6 mg/dL, the combination of 400 mg of RDEA594 and 40 mg of febuxostat resulted in an approximate 70% reduction of serum uric acid levels compared to baseline, with intraday reductions of over 80%, reaching mean serum uric acid levels of 1.2 mg/dL. These results demonstrate a robust additive effect of combining RDEA594 and febuxostat when compared to serum uric acid reductions of 49% and 45%, respectively, when each drug was administered alone in this study. There were no clinically relevant pharmacokinetic drug interactions observed with either dose tested of RDEA594 and febuxostat. RDEA594 was well tolerated with adverse events that were generally mild and transient, and no clinically significant laboratory abnormalities were observed.

    Results in Patients with Renal Impairment

    In a previously reported Phase 2a study, the efficacy response to RDEA594 in gout patients with mild-to-moderate renal impairment did not differ from that observed in patients with normal renal function. These earlier results were further confirmed by results presented at EULAR from the Phase 2b monotherapy study, as well as interim results from a study specifically evaluating the pharmacokinetics and activity of RDEA594 in patients with moderate renal impairment.

    In the Phase 2b monotherapy study, 29 patients out of a total of 96 randomized to active drug had at least mild renal impairment. Ten of these patients were classified as having moderate impairment and had a mean creatinine clearance of 46 ml/min. Patients in the Phase 2b study achieved comparable levels of uric acid reduction, irrespective of renal function at baseline.

    Ardea is also conducting a study designed specifically to evaluate the pharmacokinetics and activity of RDEA594 in patients with moderate renal impairment. Currently, four patients have completed dosing in the study. Based upon an interim analysis of completed patients, no meaningful change in the pharmacokinetics of RDEA594 has been observed in gout patients with moderate renal impairment. In addition, these patients showed an efficacy response to RDEA594 comparable to that previously seen in gout patients with normal renal function.

    Overall Safety Results

    RDEA594 was well tolerated alone or in combination with allopurinol or febuxostat in the five studies presented at EULAR, with no drug-related serious adverse events and no dose-related side effects. In the Phase 2b monotherapy study, the incidence of elevated serum creatinine levels was not significantly different across the treatment groups, including placebo, after four weeks of dosing. In addition, as previously reported and as presented at EULAR, there was no difference in the rate of transient changes in serum creatinine observed during the screening period, prior to initiation of drug treatment, and during the treatment period.

    The EULAR presentations and posters will be available on the Company's website (http://www.ardeabio.com/) under the following titles following their presentation at the conference on June 18th and 19th:

    -- Efficacy and Safety of a Range of Doses of RDEA594, a Novel Uricosuric Agent, as a Single Agent in Hyperuricemic Gout Patients: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Experience -- RDEA684, a Novel, Potent and Efficacious Inhibitor of Human Urate Transporter, URAT1, with a Favorable Pharmacokinetic Profile, and No Mitochondrial Toxicity -- Efficacy and Safety of RDEA594, a Novel Uricosuric Agent, as Combination Therapy with Allopurinol in Gout Patients: Randomized, Double-Blind, Placebo-Controlled, Phase 2 Experience -- RDEA594, a Novel Uricosuric Agent, Shows Impressive Reductions in Serum Urate Levels as Monotherapy and Substantial Additive Activity in Combination with Febuxostat in Normal Healthy Volunteers About Hyperuricemia and Gout

    Gout is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream. This leads to the deposition of painful, needle-like uric acid crystals in and around the connective tissue of the joints and in the kidneys, resulting in inflammation, the formation of disfiguring nodules (tophi), intermittent attacks of severe pain (acute flares) and kidney damage (nephropathy). In addition, evidence suggests that the chronic elevation of uric acid associated with gout, known as hyperuricemia, may also have systemic consequences, including an increased risk for kidney dysfunction and cardiovascular disease.

    In 2008, approximately 5.2 million patients in the U.S., 6.4 million patients in the European Union and 2.9 million patients in Japan were diagnosed with gout. Gout is the most common form of inflammatory arthritis in men over 40 and represents a significant medical need with limited treatment options. In the last 40 years, only one new medication has received FDA approval for the treatment of hyperuricemia associated with gout.

    About RDEA594

    Our most advanced product candidate for the treatment of hyperuricemia and gout, RDEA594, is a selective inhibitor of URAT1, a transporter in the kidney that regulates uric acid excretion from the body. Approximately 90% of gout patients are considered to be under-excretors of uric acid, and recent studies have shown that defects in renal transporters have been genetically linked to gout. Consequently, increasing renal excretion of uric acid by moderating URAT1 transporter activity may provide the most physiologically appropriate treatment for gout. In addition, because increasing the excretion of serum uric acid is additive to the effects of drugs such as allopurinol that decrease the production of uric acid, RDEA594 in combination with such drugs has the potential to treat the significant portion of the gout population that is not adequately treated with existing therapies.

    RDEA594 is in Phase 2 development as a single agent and in combination with the approved xanthine oxidase inhibitor, allopurinol. Over 500 people have received RDEA594, either by direct administration in the form currently in development or through administration of RDEA806, a prodrug of RDEA594.

    About Ardea Biosciences, Inc.

    Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhibitor program is currently in preclinical development. RDEA119, a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) and our lead product candidate for the treatment of cancer, is being developed under a global license agreement with Bayer HealthCare AG. RDEA119 is currently being evaluated in advanced cancer patients with different tumor types as a single agent in a Phase 1 study as well as in combination with sorafenib (Nexavar®; Bayer HealthCare, Onyx Pharmaceuticals) in a Phase 1/2 study. Our two product candidates for the treatment of HIV, RDEA806 and RDEA427, are non-nucleoside reverse transcriptase inhibitors (NNRTIs), which have successfully completed a Phase 2a study in HIV patients and a human micro-dose pharmacokinetic study in healthy volunteers, respectively.

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of RDEA594, RDEA119, RDEA806, RDEA427 and our other compounds and the timing and results of our preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    (Logo: http://photos.prnewswire.com/prnh/20091104/ARDEALOGO)

    (Logo: http://www.newscom.com/cgi-bin/prnh/20091104/ARDEALOGO)

    Photo: http://www.newscom.com/cgi-bin/prnh/20091104/ARDEALOGO
    http://photoarchive.ap.org/
    http://photos.prnewswire.com/prnh/20091104/ARDEALOGO
    PRN Photo Desk, photodesk@prnewswire.com Ardea Biosciences, Inc.

    CONTACT: Ardea, John Beck of Ardea Biosciences, Inc., +1-858-652-6523,
    jbeck@ardeabio.com; or Media, Heidi Chokeir, Ph.D. of Russo Partners, LLC,
    +1-619-528-2217, heidi.chokeir@russopartnersllc.com, for Ardea Biosciences,
    Inc.

    Web Site: http://www.ardeabiosciences.com/




    SPX Announces Acquisition of Innovative Process Technologies and Systems Provider AnhydroBroadens SPX's Systems Capabilities and Expands Product Portfolio for Food, Pharmaceutical and Chemical Processing

    CHARLOTTE, N.C., June 18 /PRNewswire-FirstCall/ -- SPX Corporation today announced that its Flow Technology segment has entered into a definitive agreement with Anhydro A/S and Anhydro Holding A/S to acquire the Anhydro business, a Soeborg, Denmark-based global supplier of liquid concentration equipment, powder processing solutions, and dewatering plants and equipment. The terms of the acquisition were not disclosed, and completion of the transaction is expected by the end of the third quarter 2010, subject to customary closing conditions and regulatory approvals.

    "Our process equipment business continues to be a key component of our growth strategy and this acquisition helps strengthen our global food, pharmaceutical and processing technology equipment offerings and systems capabilities," said SPX Chairman, President and Chief Executive Officer Christopher J. Kearney. "The addition of Anhydro's dry processing technology broadens our current systems capabilities beyond liquid applications, allowing us to further enhance our competencies in delivering comprehensive processing solutions to our customers."

    This transaction includes all of Anhydro's business units with the exception of its Danish Filter business, Simatek A/S, and its German, U.K., and U.S. operations, as well as certain individual projects. The acquired business units employ 225 employees and are expected to generate 2010 full year revenue of approximately 85 million Euros.

    The purchase of Anhydro is the second strategic acquisition for SPX's Flow Technology segment this year. In January, the company announced the acquisition of Denmark-based Gerstenberg Schroder, a prominent designer, manufacturer, installer and service provider of processing systems and components for the global food industry.

    "Despite the global recession, our business continues to achieve positive momentum, and we recently won our largest order in the company's history, as well as a number of other major contracts," noted Jens Logstrup, CEO of Anhydro. "We believe now is the opportune time to begin a new chapter in Anhydro's evolution. Moreover, we see SPX's broad portfolio of processing equipment and solutions as a natural fit with our product offerings, and are confident that SPX Corporation's expanding global reach will further enhance our prospects for future growth."

    About Anhydro

    Anhydro supplies a complete range of evaporation and drying solutions for dairy, food, and starch producers and for the chemical and pharmaceutical industries worldwide. The company's focus on flexibility and individual customer needs secure optimal results in every link of the value chain. Anhydro is a strategic partner to leading producers all over the world. Through close cooperation with its customers, Anhydro drives the development of innovative concepts and optimization of existing processes, which enables customers to develop and introduce new products quickly and cost efficiently. More information can be found at http://www.anhydro.com/.

    About SPX

    SPX Corporation is a Fortune 500 multi-industry manufacturing leader that provides its customers with highly-specialized, engineered solutions to solve critical business issues.

    SPX products and technologies play an important role in the expansion of global infrastructure to help meet increased demand for power and energy and support many different sources of power generation, including coal and natural gas, nuclear, solar and geothermal. The company's innovative product portfolio, containing many energy efficient products, includes cooling systems for power plants throughout the world; highly advanced food processing components and turnkey, scalable systems serving the global food and beverage industry; process equipment that assists a variety of flow processes including oil and gas exploration, distribution and refinement and power generation; handheld diagnostic tools that aid in vehicle maintenance and repair; and power transformers that allow utility companies to regulate electric voltage, transmission and distribution.

    With headquarters in Charlotte, North Carolina, SPX has 15,000 employees in more than 35 countries worldwide. Visit http://www.spx.com/.

    Certain statements in this press release including any statements relating to consummation of the contemplated transaction or post- acquisition results, may be forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. Please refer to our public filings for a discussion of certain important factors that relate to forward-looking statements contained in this press release. The word "expect," "believe" and similar expressions may identify forward-looking statements. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Statements in the press release speak only as of the date of this press release, and SPX disclaims any responsibility to update or revise such statements.

    SPX Corporation

    CONTACT: Ryan Taylor (Investors), +1-704-752-4486, investor@spx.com, or
    Jennifer H. Epstein (Media), +1-704-752-7403, jennifer.epstein@spx.com

    Web Site: http://www.spx.com/




    Charm Promotes Linna Li to CCTV Buying Platform Vice President

    Company Remains Focused on Obtaining Top Tier Media for Blue-chip Advertisers

    - Appoints Media Buying Expert to its Service Solution Committee

    BEIJING, June 18 /PRNewswire-Asia-FirstCall/ -- Charm Communications Inc. ("Charm" or the "Company"), a leading advertising agency in China, today announced that it has promoted Ms. Linna Li to vice president in charge of Charm's CCTV buying platform with immediate effect.

    As a vice president of the company Ms. Li will join Charm's Service Solution Committee, which has been formed to uphold and promote the highest standards of professional service and industry best practice across all of Charm's business segments. By bringing together key executives from different disciplines within the firm, Charm will create important synergies and allow the cross cultivation of ideas throughout the company. Ms. Li's in-depth knowledge of top tier media buying will be an important asset for all of Charm's business segments and clients.

    "CCTV is the most important and authoritative media platform in China, on which any blue-chip advertiser that has ambitions to become a national brand chooses to advertise, and this appointment recognizes the central part that Ms. Li has played in building up our industry leading CCTV buying platform," commented He Dang, founder, chairman and CEO of Charm. "Ms. Li will be leveraging her considerable experience to expand her team and ensure that our servicing of clients' CCTV requirements is maintained at the highest levels as we enhance our agency business' nationwide coverage."

    Ms. Li has built her career with Charm gaining a wealth of experience in the advertising industry over 13 years with the company, and has extensive specialist knowledge of media buying. Her knowledge and dedication have made a significant contribution to building Charm's agency business and helped make Charm the largest buyer of CCTV media resources for each of the last 6 years.

    Ms. Li holds a master's degree in economics from China's Social Science Institute.

    About Charm

    Charm Communications Inc. is a leading domestic television advertising agency in China. Charm operates its business under three brands: Charm Advertising, Charm Interactive, and Shangxing Media. Under the Charm Advertising and Charm Interactive brands, Charm offers integrated advertising agency services from planning and managing advertising campaigns to creating and placing advertisements. Under the Shangxing Media brand, Charm has established a portfolio of television advertising media resources through its exclusive arrangements with four programs on CCTV, and two satellite television channels, Shanghai Dragon TV and Tianjin Satellite TV, which includes not only advertising time but also opportunities for placing branded content. Charm's clients include well-recognized brand names in China across many industries, as well as emerging domestic leading brands. In January 2010, Charm formed a joint venture with international 4A advertising group Aegis Media, its strategic investor, to operate its brand "Vizeum" in China. For more information please go to http://ir.charmgroup.cn/ .

    For investor and media inquiries, please contact: New York Amanda Sham Brunswick Group Phone: +1-212-333-3810 Email: charm@brunswickgroup.com Beijing Henry Fraser Brunswick Group Phone: +86-10-6566-2256 Email: charm@brunswickgroup.com

    Charm Communications Inc.

    CONTACT: New York: Amanda Sham, Brunswick Group at +1-212-333-3810 or
    charm@brunswickgroup.com; Beijing: Henry Fraser, Brunswick Group at
    +86-10-6566-2256 or charm@brunswickgroup.com

    Web site: http://ir.charmgroup.cn/




    Charm Promotes Yihe Zhao to Market Research Vice President

    Company Seeks to Strengthen Consumer Behavior Research Initiatives by Appointing Research Specialist to its Service Solution Committee

    BEIJING, June 18 /PRNewswire-Asia-FirstCall/ -- Charm Communications Inc. ("Charm" or the "Company"), a leading advertising agency in China, today announced that it has promoted Mr. Yihe Zhao to vice president in charge of market research with immediate effect.

    As a vice president of the company Mr. Zhao will join Charm's Service Solution Committee, which has been formed to uphold and promote the highest standards of professional service and industry best practice across all of Charm's business segments. By bringing together key executives from different disciplines within the firm, Charm will create important synergies and allow the cross cultivation of ideas throughout the Company. Market research has never been more important and Mr. Zhao's singular expertise will be shared within the Company through Charm's Service Solution Committee, bringing benefits to all business segments.

    "Researching the market, consumers and branding is the foundation for all integrated communications in the dynamic and fast-developing market in China," commented He Dang, founder, chairman and CEO of Charm. "Going forward, as head of our leading market research center, Mr. Zhao will be an invaluable asset to help us develop innovative advanced research tools and technologies and ensure that we apply our market positioning strategy across the board to improve our professional capabilities and provide enhanced client service."

    Mr. Zhao joined Charm in May 2008 to run the market and media research department. He has over 15 years of experience in the advertising industry, with extensive knowledge of consumer behavior studies, marketing strategy, media research and brand research. Since he has been in the industry, Mr. Zhao has worked with over 100 brands, servicing many major international and domestic companies including China Telecom, Midea, Mengniu, Kia, Lotte and American Dairy and has received numerous industry awards for his work. This experience has given Mr. Zhao a deep understanding of the local market and what it takes for a brand to become ubiquitous. Mr. Zhao is also a published author, having written 'Core Changes - Building Strong Brands Faster,' in 2003, and is a featured lecturer at Tsinghua University's MBA Programs and China's 4A Association.

    Yihe Zhao has a bachelor's degree in advertising from Nanjing University of Finance and Economics.

    About Charm

    Charm Communications Inc. is a leading domestic television advertising agency in China. Charm operates its business under three brands: Charm Advertising, Charm Interactive, and Shangxing Media. Under the Charm Advertising and Charm Interactive brands, Charm offers integrated advertising agency services from planning and managing advertising campaigns to creating and placing advertisements. Under the Shangxing Media brand, Charm has established a portfolio of television advertising media resources through its exclusive arrangements with four programs on CCTV, and two satellite television channels, Shanghai Dragon TV and Tianjin Satellite TV, which includes not only advertising time but also opportunities for placing branded content. Charm's clients include well-recognized brand names in China across many industries, as well as emerging domestic leading brands. In January 2010, Charm formed a joint venture with international 4A advertising group Aegis Media, its strategic investor, to operate its brand "Vizeum" in China. For more information please go to http://ir.charmgroup.cn/ .

    For investor and media inquiries, please contact: New York Amanda Sham Brunswick Group Phone: +1-212-333-3810 Email: charm@brunswickgroup.com Beijing Henry Fraser Brunswick Group Phone: +86-10-6566-2256 Email: charm@brunswickgroup.com

    Charm Communications Inc.

    CONTACT: New York: Amanda Sham, Brunswick Group at +1-212-333-3810 or
    charm@brunswickgroup.com; Beijing: Henry Fraser, Brunswick Group at
    +86-10-6566-2256 or charm@brunswickgroup.com

    Web site: http://ir.charmgroup.cn/




    Sinovac Schedules 2010 Annual Meeting of Shareholders

    BEIJING, June 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. , a leading developer and provider of vaccines in China, announced today that it will hold its 2010 Annual Meeting of Shareholders on Thursday, July 15, 2010 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC and at No. 6 Temple Street, St. John's, Antigua. All shareholders of record as of May 26, 2010 will be eligible to vote and are invited to attend. Sinovac 2009 annual report and the proxy statements are also be available on the company's website: http://www.sinovac.com/Investors/SECFilings/ http://www.sinovac.com/Investors/IRHome/presentation/.

    About Sinovac

    Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Its 30%-owned joint venture, Sinovac Dalian, focuses on the research, development, manufacturing and commercialization of vaccines, such as rabies, chickenpox, mumps and rubella vaccines for human use.

    For more information, please contact: Chris Lee Sinovac Biotech Ltd. Tel: +86-10-8279-9659 Fax: +86-10-6296-6910 Email: lill@sinovac.com Investors: Amy Glynn/Stephanie Carrington The Ruth Group Tel: +1-646-536-7023/7017 Email: aglynn@theruthgroup.com scarrington@theruthgroup.com Media: Jason Rando The Ruth Group Tel: +1-646-536-7025 Email: jrando@theruthgroup.com

    Sinovac Biotech Ltd.

    CONTACT: Chris Lee of Sinovac Biotech Ltd., +86-10-8279-9659 (Tel), or
    +86-10-6296-6910 (Fax), or lill@sinovac.com; or Investors: Amy Glynn/Stephanie
    Carrington of The Ruth Group, +1-646-536-7023/7017, or aglynn@theruthgroup.com
    / scarrington@theruthgroup.com; or Media: Jason Rando of The Ruth Group,
    +1-646-536-7025, or jrando@theruthgroup.com

    Web site: http://www.sinovac.com/Investors/SECFilings




    China Finance Online Hosted Shanghai-Themed Investment Forum

    BEIJING, June 18 /PRNewswire-Asia/ -- China Finance Online Co., Ltd. ("China Finance Online"," the Company") , the technology-driven, user-focused market leader in China in providing vertically integrated financial services and products including news, data, analytics and brokerage through web portals, software systems, and mobile handsets, today announced that stockstar.com, a leading securities web portal owned by the Company, successfully hosted Shanghai-themed investment forum "Shanghai Triumph", for Chinese investors from May 17th through June 12th.

    In response to the State Council's strategic plan to build Shanghai into a global financial center by 2020, Shanghai Triumph forum facilitated open discussions, evaluations and rankings of publicly listed companies which are closely related to the city of Shanghai, based on various financial metrics, as well as fair evaluation standards and stringent voting procedure. These 164 publicly listed companies that are either registered in or have substantial operations concentrated in Shanghai, were selected from various industries such as financial services, real estate, shipping, manufacturing etc. Based on online voting and specialist assessment, awards were given for "Best Earning Power", "Best Return on Investment", "Best Dividend Program" and other 5 categories. China Finance Online also hosted an award ceremony on June 12th, which attracted a large number of academics and government officials, and senior executives from approximately 150 public companies.

    Mr. Zhiwei Zhao, Chief Executive Officer of China Finance Online, stated, "While World Expo is bringing global attention to Shanghai, we are also very excited to have organized and hosted this Shanghai-themed investment forum. Shanghai Triumph gained considerable popularity by attracting well over 1 million votes and coverage from 40 media reports throughout the event. More importantly, to further complement our product offerings, we continue to introduce innovative and interactive web-events to engage and educate vast Chinese retail investors to discover undervalued companies, identify best practices and discuss sustainable investment theories. On the other side, we continue to leverage our brand name to cement our relationships with public companies and financial media to generate buzz and attract more investors to register on our evolving 'one-stop' financial information platform."

    About China Finance Online

    China Finance Online Co. Limited is the technology-driven, user-focused market leader in China in providing vertically integrated financial services and products including news, data, analytics and brokerage through web portals, software systems, and mobile handsets. Through its web portals, http://www.jrj.com/ and http://www.stockstar.com/, the Company provides individual users with subscription-based service packages that integrate financial and listed-company data, information and analytics from multiple sources with features and functions such as data and information search, retrieval, delivery, storage and analysis. These features and functions are delivered through proprietary software available by download, through the internet or through mobile handsets. Through its subsidiary, Genius, the Company provides financial information database and analytics to institutional customers including domestic securities and investment firms. Through its subsidiary, Daily Growth, the Company provides securities brokerage services for stocks listed on Hong Kong Stock Exchange.

    Safe Harbor Statement

    This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's strategic operational plans and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The Company believes that the Chinese economy continues to expand; however, the expansion may be uneven with certain sectors being affected more than others with resulting volatility in the Chinese equity market which could influence the Company's operating results in the coming quarters. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    For more information, please contact: In China: Melissa Zhang Investor Relations China Finance Online Co., Ltd. Email: ir@jrj.com In the United States: Kevin Theiss Grayling Tel: +1-646-284-9409 Email: kevin.theiss@grayling.com

    China Finance Online Co. Limited

    CONTACT: In China: Melissa Zhang, Investor Relations, China Finance
    Online Co., Ltd., ir@jrj.com; or In the United States: Kevin Theiss, Grayling,
    +1-646-284-9409, or kevin.theiss@grayling.com




    New Energy Systems Group Creates Audit, Compensation and Nominating Committees

    Satisfies Additional Requirement for Listing on Senior U.S. Stock Exchange

    NEW YORK and SHENZHEN, China, June 18 /PRNewswire-Asia-FirstCall/ -- New Energy Systems Group (BULLETIN BOARD: NEWN) ("New Energy"), a vertically integrated original design manufacturer and distributor of lithium ion batteries and backup power systems, today announced its Board of Directors has established audit, compensation and nominating committees.

    Mr. Nian Chen, Chief Executive Officer, commented, "We are pleased to have established our audit, compensation and nominating committees, which reflects our commitment to meeting the highest standards of corporate governance. In addition to serving critical internal management and corporate governance functions, this development also satisfies another important prerequisite for listing our stock on a senior U.S. stock exchange."

    Copies of the charter documents for the audit, compensation and nominating committees are available for review on the New Energy corporate website located at http://www.newenergysystemsgroup.com/ .

    About New Energy Systems Group

    New Energy Systems Group is a vertically integrated original design manufacturer and distributor of lithium ion batteries and backup power systems for mobile phones, laptops, digital cameras, MP3s and a variety of other portable electronics. The company's end-user consumer products are sold under the Anytone brand in China, and the company has begun expanding its international sales efforts. The fast pace of new mobile device introductions in China combined with a growing middle class make it fertile ground for New Energy's end-user consumer products as well as its high-powered, lightweight lithium ion batteries. In addition to historically strong organic growth, New Energy anticipates that it will benefit from economies of scale, broader distribution, greater production capacity and higher profit margins in 2010. Additional information about the company is available at: http://www.newenergysystemsgroup.com/ .

    Forward Looking Statements

    This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary and affiliated companies. These forward looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov/). All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.

    For more information, please contact: Crescendo Communications, LLC David Waldman or John Quirk Tel: +1-212-671-1020 Email: newn@crescendo-ir.com

    New Energy Systems Group

    CONTACT: David Waldman or John Quirk, Crescendo Communications, LLC at
    +1-212-671-1020 or newn@crescendo-ir.com

    Web site: http://www.newenergysystemsgroup.com/




    TreeHouse Foods Announces Webcast of Second Quarter 2010 Earnings Results Conference Call

    WESTCHESTER, Ill., June 18 /PRNewswire-FirstCall/ -- TreeHouse Foods, Inc. will host a live audio Webcast of its second quarter earnings results conference call on Thursday, August 5, 2010 at 9:00 a.m. EDT. Management will discuss the results for the second quarter. An earnings release will be issued before the market opens on the same date. The Webcast will last approximately one hour and will be accessible by visiting http://www.treehousefoods.com/ and by clicking on "Calendar of Events" under "Investor Relations."

    In order to listen to the Webcast, users will need to have installed either Real Player or Windows Media Player software, which can be detected and downloaded by visiting the site. A Webcast replay will be available for one year following the event within the Investor Relations, Calendar of Events section of the Company's Website.

    ABOUT TREEHOUSE FOODS

    TreeHouse is a food manufacturer servicing primarily the retail grocery and foodservice channels. Its products include non-dairy powdered coffee creamer; canned soup, salad dressings and sauces; sugar free drink mixes and sticks, instant oatmeal and hot cereals, salsa and Mexican sauces; jams and pie fillings under the E.D. Smith brand name; pickles and related products; infant feeding products; and other food products including aseptic sauces, refrigerated salad dressings, and liquid non-dairy creamer. TreeHouse believes it is the largest manufacturer of pickles and non-dairy powdered creamer in the United States and the largest manufacturer of private label salad dressings, drink mixes and instant hot cereals in the United States and Canada based on sales volume.

    Additional information, including TreeHouse's most recent statements on Forms 10-Q and 10-K, may be found at TreeHouse Foods' website, http://www.treehousefoods.com/.

    Photo: http://www.newscom.com/cgi-bin/prnh/20050726/CGTREELOGO
    AP Archive: http://photoarchive.ap.org/
    http://photos.prnewswire.com/prnh/20050726/CGTREELOGO
    PRN Photo Desk, photodesk@prnewswire.com TreeHouse Foods, Inc.

    CONTACT: Investor Relations of TreeHouse Foods, Inc., +1-708-483-1300
    Ext. 1331

    Web Site: http://www.treehousefoods.com/




    Alliant Energy Requests Proposals for Sale of Industrial Energy Applications, Inc.

    MADISON, Wis., June 18 /PRNewswire-FirstCall/ -- Alliant Energy Corporation announced today that Alliant Energy Resources, LLC ("AER") is seeking proposals for the sale of Industrial Energy Applications, Inc. (IEA). IEA is a wholly-owned subsidiary of AER that provides facilities-based energy services to businesses in the Midwest. IEA currently owns and operates 59 natural gas and diesel fueled generators located in Iowa and South Dakota (aggregate installed capacity of approximately 80 megawatts) which provide reliable power to its customers during unexpected or prolonged power outages. IEA also owns and operates a steam production facility utilized by a dairy cooperative located in Wisconsin.

    (Logo: http://photos.prnewswire.com/prnh/20020405/LNTLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20020405/LNTLOGO)

    AER has asked for proposals to be received by 2:00 pm EDT on July 14, 2010.

    Additional information regarding IEA is available at http://www.alliantenergy.com/Non-Utility/IndustrialEnergyApplications.

    Alliant Energy is an energy-services provider with subsidiaries serving approximately 1 million electric and over 412,000 natural gas customers. Providing its customers in the Midwest with regulated electric and natural gas service is the company's primary focus. Alliant Energy's utility subsidiaries are Interstate Power and Light and Wisconsin Power and Light companies. Alliant Energy, headquartered in Madison, Wis., is a Fortune 1000 company traded on the New York Stock Exchange under the symbol LNT. For more information, visit the company's Web site at http://www.alliantenergy.com/.

    ANR119-06

    Photo: http://www.newscom.com/cgi-bin/prnh/20020405/LNTLOGO
    AP Archive: http://photoarchive.ap.org/
    http://photos.prnewswire.com/prnh/20020405/LNTLOGO
    PRN Photo Desk, photodesk@prnewswire.com Alliant Energy Corporation

    CONTACT: media, Scott Reigstad, +1-608-458-3145, or investor relations,
    Susan Gille, +1-608-458-3956, both for Alliant Energy Corporation

    Web Site: http://www.alliantenergy.com/




    Rentrak Announces Top Ten Movies-on-Demand Titles Week Ending June 13, 2010

    PORTLAND, Ore., June 18 /PRNewswire-FirstCall/ -- Rentrak Corporation , today announced the top ten movies-on-demand (VOD) titles based on consumer transaction rate. Movies-on-demand are transactional (pay-per-purchase) films available through cable and telco providers.

    According to the company's OnDemand Essentials service, the top ten most-viewed titles, per data collected from June 7, 2010 through June 13, 2010 include:

    Rentrak Top Ten VOD Titles -------------------------- VOD RELEASE MPAA BOX OFFICE RANK TITLE STUDIO DATE RATING ($M) ---- ----- ------ ----------- ------ ---------- 1 Shutter Island* Paramount 6/08/10 R 128.0 --- --------------- --------- ------- --- ----- (NYSE: VIA; VIA.B) ----------- From Paris with 2 Love* Lionsgate 6/08/10 R 24.1 --- --------------- --------- ------- --- ---- ----------- 3 Alice in Wonderland Buena Vista 6/11/10 PG 333.9 --- ------------------- ----------- ------- --- ----- ----------- 4 The Wolfman* Universal 6/01/10 NR 62.0 --- ------------ --------- ------- --- ---- ---------- 5 Legion Sony 6/10/10 R 40.1 --- ------ ---- ------- --- ---- ----------- 6 Valentine's Day* Warner Bros. 5/18/10 PG-13 110.5 --- ---------------- ------------ ------- ----- ----- ----------- 7 Dear John* Sony 5/25/10 PG-13 80.0 --- ---------- ---- ------- ----- ---- ----------- 8 Avatar FOX 5/09/10 PG-13 748.0 --- ------ --- ------- ----- ----- ------------- 9 The Young Victoria Sony 6/04/10 PG 11.0 --- ------------------ ---- ------- --- ---- ----------- 10 It's Complicated* Universal 4/27/10 R 112.7 --- ----------------- --------- ------- --- ----- ---------- Source: Rentrak OnDemand Essentials, as dated, rank based on Transaction Rate. OnDemand Essentials includes reporting from Operator partners on Television On Demand usage. * Indicates day- and-date with home video release.

    © Rentrak Corporation 2010 -Content in this chart is produced and/or compiled by Rentrak Corporation and its OnDemand Essentials data collection and analytical service, and is covered by provisions of the Copyright Act. The material presented herein is intended to be available for public use. You may reproduce the content of the chart in any format or medium without first obtaining permission, subject to the following requirements: (1) the material must be reproduced accurately; and (2) any publication or issuance of any part of the material to others must acknowledge Rentrak Corporation as the source of the material.

    About OnDemand Essentials®

    OnDemand Essentials, a service of Rentrak's Advanced Media & Information Division, provides operators, content providers (including broadcast/cable networks, studios) and advertisers with a transactional tracking and reporting system to view and analyze on-demand content. The product is an extension of Rentrak's Essentials suite of business intelligence products customized for the entertainment industry. OnDemand Essentials clients have password protected, near real-time, Web browser-based 24/7 access to on demand consumer usage data at various access levels based on business and privacy rules. A sophisticated toolset aggregates and reports data across multiple vendors in one easy to use report system. Clients using the OnDemand Essentials system are able to instantly analyze and interpret their own business data to identify trends, program and promote more effectively, as well as track their performance against the broader business sector in which they operate.

    About Rentrak Corporation

    Rentrak Corporation is a global digital media measurement and research company, serving the most recognizable companies in the entertainment industry. With a reach across numerous platforms including box office, home entertainment, video on demand and linear television, broadband and mobile, Rentrak has developed more efficient metrics to be used as alternative currencies for the evaluation and selling of media. Rentrak is headquartered in Portland, Oregon, with additional offices worldwide. For more information on any of Rentrak's services, please visit http://www.rentrak.com/.

    Contacts: Rogers & Cowan for Rentrak Corporation Sallie Olmsted Amanda Bialek (310) 854-8124 (310) 854-8151 solmsted@rogersandcowan.com abialek@rogersandcowan.com

    Rentrak Corporation

    CONTACT: Sallie Olmsted, +1-310-854-8124, solmsted@rogersandcowan.com,
    or Amanda Bialek, +1-310-854-8151, abialek@rogersandcowan.com, both of Rogers
    & Cowan for Rentrak Corporation

    Web Site: http://www.rentrak.com/




    MSC Industrial Direct Co., Inc. to Broadcast Review of Third Quarter 2010 Results Over the Internet

    MELVILLE, N.Y., June 18 /PRNewswire-FirstCall/ -- MSC INDUSTRIAL DIRECT CO., INC. , "MSC" or the "Company," one of the largest direct marketers and premier distributors of Metalworking and Maintenance, Repair and Operation ("MRO") supplies to industrial customers throughout the United States, today announced that the Company's conference call to review third quarter 2010 results, as well as current operations, will be broadcast live over the Internet on Thursday, July 1, 2010 at 11:00 a.m. Eastern Time.

    To access the call, please visit the following web address: http://www.mscdirect.com/

    An online archive of the broadcast will be available within one hour of the conclusion of the call and will be available for two weeks.

    About MSC Industrial Direct Co., Inc.

    MSC Industrial Direct Co., Inc. is one of the largest direct marketers and premier distributors of Metalworking and Maintenance, Repair and Operations ("MRO") supplies to industrial customers throughout the United States. MSC distributes approximately 600,000 industrial products from approximately 3,000 suppliers to approximately 330,000 customers. In-stock availability is approximately 99%, with next day standard delivery to the contiguous United States on qualifying orders up until 8:00 p.m. Eastern Time. MSC reaches its customers through a combination of approximately 29 million direct-mail catalogs and CD-ROMs, 95 branch sales offices, 949 sales people, the Internet and associations with some of the world's most prominent B2B eCommerce portals. For more information, visit the Company's website at http://www.mscdirect.com/.

    CAUTIONARY STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. Statements in this Press Release may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein which are not statements of historical facts and that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future, including statements about future expected net sales and diluted earnings per share and expectations as to revenue, earnings and margin growth, shall be deemed to be forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy and some of which might not even be anticipated. Future events, actual results and performance, financial and otherwise, could differ materially from those set forth in or contemplated by the forward-looking statements herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The inclusion of any statement in this release does not constitute an admission by MSC or any other person that the events or circumstances described in such statement are material. Factors that could cause actual results to differ materially from those in forward-looking statements include, without limitation, current economic, political and social conditions, changing customer and product mixes, financial restrictions on outstanding borrowings, industry consolidation, competition, general economic conditions in the markets in which the Company operates, volatility in commodity and energy prices, credit risk of our customers, risk of cancellation or rescheduling of orders, work stoppages or other business interruptions (including those due to extreme weather conditions) at transportation centers or shipping ports, the risk of war, terrorism and similar hostilities, dependence on the Company's information systems and on key personnel, and the outcome of potential government or regulatory proceedings or future litigation relating to pending or future claims, inquiries or audits. Additional information concerning these and other risks is described under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's reports on Forms 10-K, 10-Q and 8-K that the Company files with the U.S. Securities and Exchange Commission. The forward-looking statements in this press release are based on current expectations and the Company assumes no obligation to update these forward-looking statements.

    MSC Industrial Direct Co., Inc.

    CONTACT: Shelley Boxer, V.P. Finance, MSC Industrial Direct Co., Inc.,
    +1-516-812-1216; Investors/Media: Eric Boyriven or Alexandra Tramont, FD,
    +1-212-850-5600

    Web Site: http://www.mscdirect.com/




    MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men

    NATICK, Massachusetts and NICE, France, June 18, 2010 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from a sub-analysis of the MADIT-CRT trial data that showed women received a greater clinical benefit from its cardiac resynchronization therapy defibrillators (CRT-Ds) than men. The results were presented during the 17th Cardiostim World Congress by Jonathan Steinberg, M.D., Chief of Cardiology and Director of the Al-Sabah Arrythmia Institute, St. Luke's-Roosevelt Hospital Center, New York.

    The sub-analysis demonstrated that both men and women experienced significant benefit from cardiac resynchronization therapy. However, women experienced a 70 percent reduction in heart failure events compared to a 35 percent reduction for men. Additional analysis demonstrated that women with asymptomatic or mild heart failure experienced a 72 percent reduction in all-cause mortality.

    "There are a number of factors that may explain why women experienced a greater benefit than men," said Arthur Moss, M.D., Professor of Medicine at the University of Rochester Medical Center and Principal Investigator of the MADIT-CRT trial. "CRT-D therapy is designed to improve the heart's overall pumping ability and women are more likely than men to have non-ischemic heart disease, which typically affects the entire heart rather than a single region and can lead to reduced pumping strength, abnormal heart rhythms and disturbances in the heart's electrical system. Men are more likely to have ischemic heart disease, also known as coronary artery disease, which often leads to a more localized impact on the heart."

    "These findings are noteworthy because CRT-D therapy has historically been underutilized in women compared to men with the same level of heart disease," said Kenneth Stein, M.D., Chief Medical Officer, CRM, for Boston Scientific's Cardiology, Rhythm and Vascular Group. "Boston Scientific believes that all patients should have equal access to high-quality cardiovascular care regardless of gender. We believe these findings will help reduce treatment disparities between men and women."

    MADIT-CRT is the world's largest randomized CRT-D study of New York Heart Association (NYHA) Class I and II patients[1], with more than 1,800 patients enrolled at 110 centers worldwide. Results of the MADIT-CRT trial were published in the October 2009 issue of the New England Journal of Medicine. Boston Scientific currently has an application under review with the U.S. Food and Drug Administration for the expansion of its CRT-D indication to include high-risk[2] NYHA Class I and II patients with Left Bundle Branch Block.

    Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, clinical outcomes, regulatory approval of our products, and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

    Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    ---------------------------------

    [1] The NYHA clinical classifications of heart failure rank patients as Class I-II-III-IV, according to the degree of symptoms or functional limits, from asymptomatic to bed ridden. MADIT-CRT patients are asymptomatic or mildly symptomatic, NYHA Class I (ischemic) and Class II (ischemic and non-ischemic).

    [2] High-risk is defined as QRS width >130 milliseconds with Left Ventricular Ejection Fraction < 30 percent and Left Bundle Branch Block (LBBB). LBBB is a condition in which the activation of the left ventricle is delayed. As a result, portions of the left ventricle contract later than the rest of the left ventricle and right ventricle, reducing the heart's pumping ability.

    Contact: Paul Donovan +1-508-650-8541 (office) +1-508-667-5165 (mobile) Media Relations Boston Scientific Corporation David Knutson +1-651-582-6574 (office) +1-651-260-8288 (mobile) Media Relations Boston Scientific Corporation Larry Neumann +1-508-650-8696 (office) Investor Relations Boston Scientific Corporation

    Boston Scientific Corporation

    Contact: Paul Donovan, +1-508-650-8541 (office), +1-508-667-5165 (mobile), Media Relations, Boston Scientific Corporation; David Knutson, +1-651-582-6574 (office), +1-651-260-8288 (mobile), Media Relations, Boston Scientific Corporation; Larry Neumann, +1-508-650-8696 (office), Investor Relations, Boston Scientific Corporation




    MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men

    NATICK, Massachusetts and NICE, France, June 18, 2010 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced results from a sub-analysis of the MADIT-CRT trial data that showed women received a greater clinical benefit from its cardiac resynchronization therapy defibrillators (CRT-Ds) than men. The results were presented during the 17th Cardiostim World Congress by Jonathan Steinberg, M.D., Chief of Cardiology and Director of the Al-Sabah Arrythmia Institute, St. Luke's-Roosevelt Hospital Center, New York.

    The sub-analysis demonstrated that both men and women experienced significant benefit from cardiac resynchronization therapy. However, women experienced a 70 percent reduction in heart failure events compared to a 35 percent reduction for men. Additional analysis demonstrated that women with asymptomatic or mild heart failure experienced a 72 percent reduction in all-cause mortality.

    "There are a number of factors that may explain why women experienced a greater benefit than men," said Arthur Moss, M.D., Professor of Medicine at the University of Rochester Medical Center and Principal Investigator of the MADIT-CRT trial. "CRT-D therapy is designed to improve the heart's overall pumping ability and women are more likely than men to have non-ischemic heart disease, which typically affects the entire heart rather than a single region and can lead to reduced pumping strength, abnormal heart rhythms and disturbances in the heart's electrical system. Men are more likely to have ischemic heart disease, also known as coronary artery disease, which often leads to a more localized impact on the heart."

    "These findings are noteworthy because CRT-D therapy has historically been underutilized in women compared to men with the same level of heart disease," said Kenneth Stein, M.D., Chief Medical Officer, CRM, for Boston Scientific's Cardiology, Rhythm and Vascular Group. "Boston Scientific believes that all patients should have equal access to high-quality cardiovascular care regardless of gender. We believe these findings will help reduce treatment disparities between men and women."

    MADIT-CRT is the world's largest randomized CRT-D study of New York Heart Association (NYHA) Class I and II patients[1], with more than 1,800 patients enrolled at 110 centers worldwide. Results of the MADIT-CRT trial were published in the October 2009 issue of the New England Journal of Medicine. Boston Scientific currently has an application under review with the U.S. Food and Drug Administration for the expansion of its CRT-D indication to include high-risk[2] NYHA Class I and II patients with Left Bundle Branch Block.

    Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, clinical outcomes, regulatory approval of our products, and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

    Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    ---------------------------------

    [1] The NYHA clinical classifications of heart failure rank patients as Class I-II-III-IV, according to the degree of symptoms or functional limits, from asymptomatic to bed ridden. MADIT-CRT patients are asymptomatic or mildly symptomatic, NYHA Class I (ischemic) and Class II (ischemic and non-ischemic).

    [2] High-risk is defined as QRS width >130 milliseconds with Left Ventricular Ejection Fraction < 30 percent and Left Bundle Branch Block (LBBB). LBBB is a condition in which the activation of the left ventricle is delayed. As a result, portions of the left ventricle contract later than the rest of the left ventricle and right ventricle, reducing the heart's pumping ability.

    Contact: Paul Donovan +1-508-650-8541 (office) +1-508-667-5165 (mobile) Media Relations Boston Scientific Corporation David Knutson +1-651-582-6574 (office) +1-651-260-8288 (mobile) Media Relations Boston Scientific Corporation Larry Neumann +1-508-650-8696 (office) Investor Relations Boston Scientific Corporation

    Boston Scientific Corporation

    CONTACT: Contact: Paul Donovan, +1-508-650-8541 (office),
    +1-508-667-5165 (mobile), Media Relations, Boston Scientific Corporation;
    David Knutson, +1-651-582-6574 (office), +1-651-260-8288 (mobile), Media
    Relations, Boston Scientific Corporation; Larry Neumann, +1-508-650-8696
    (office), Investor Relations, Boston Scientific Corporation




    Rentrak to Present at the Advanced Advertising 2.0 Conference Presented by Broadcasting & Cable and Multichannel News

    PORTLAND, Ore., June 18 /PRNewswire-FirstCall/ -- Rentrak Corporation , the leader in multi-screen media measurement serving the advertising and entertainment industries, today announced that Bruce Goerlich, Rentrak's Chief Research Officer, will serve as a panelist during the Advanced Advertising 2.0 conference. The event is presented by Broadcasting & Cable and Multichannel News and will focus discussion on two key topics: Two-Way Marketing Engine and Viewer Measurement.

    As an authority on the subject, Rentrak's Bruce Goerlich was tapped to be a featured panelist on the "Viewer Measurement: State of the Art" panel. Mr. Goerlich will provide an overview of current measurement technologies while identifying opportunities for the evolution of the industry based on Rentrak's cutting-edge TV measurement services.

    The Advanced Advertising 2.0 conference takes place on Monday, June 21 from 3:00 p.m. to 6:00 p.m. (EDT) at the Marriott Marquis, located at 1535 Broadway in New York City.

    About Rentrak Corporation

    Rentrak Corporation is a global digital media measurement and research company, serving the most recognizable companies in the entertainment industry. With a reach across numerous platforms including box office, home entertainment, video on demand and linear television, broadband and mobile, Rentrak has developed more efficient metrics to be used as alternative currencies for the evaluation and selling of media. Rentrak is headquartered in Portland, Oregon, with additional offices worldwide. For more information on any of Rentrak's services, please visit http://www.rentrak.com/.

    Contact for Rentrak Corporation: Sallie Olmsted / Amanda Bialek Office: 310-854-8124 / 310-854-8151 E-mail: solmstead@rogersandcowan.com / abialek@rogersandcowan.com

    Rentrak Corporation

    CONTACT: Sallie Olmsted, +1-310-854-8124, solmstead@rogersandcowan.com,
    or Amanda Bialek, +1-310-854-8151, abialek@rogersandcowan.com, both for
    Rentrak Corporation

    Web Site: http://www.rentrak.com/




    Dollar Thrifty Automotive Group Completes New $300 Million Asset Backed Financing

    TULSA, Okla., June 18 /PRNewswire-FirstCall/ -- Dollar Thrifty Automotive Group, Inc. today announced that its Rental Car Finance Corp. subsidiary completed a private placement of Rental Car Asset Backed Variable Funding Notes, Series 2010-2. When fully funded, the notes will provide $300 million of additional fleet financing. The revolving period for the notes ends in June 2013, with scheduled amortization payments due over a six-month period beginning in July 2013 and ending in December 2013. The notes will bear interest at a spread of 375 basis points above the one-month LIBOR rate when drawn. The notes have an advance rate of approximately 65%.

    (Logo: http://photos.prnewswire.com/prnh/20020412/DTGLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20020412/DTGLOGO)

    "We have added $500 million of vehicle financing capacity during the first six months of 2010, demonstrating our ability to access the markets at competitive interest rates and enhancement levels," said Scott L. Thompson, President and Chief Executive Officer. "This transaction provides the Company with additional long-term fleet financing capacity well in advance of our next scheduled fleet debt maturity, at a rate that is below the effective fixed rates of interest paid in respect of our existing medium term notes."

    The Company noted that its next scheduled fleet debt maturity begins in December 2010 when $600 million of its Series 2006-1 notes begin amortizing over a six-month period ending in May 2011. The Company also noted that it has no significant scheduled corporate debt maturities until June 2013, when borrowings under the Company's existing Senior Secured Credit Facility come due and the Facility terminates.

    "Subject to market conditions, we expect to complete an additional $300 million of fleet financing during the fourth quarter of 2010, which will, when combined with the availability under the new Series 2010-2 notes, provide adequate replacement financing for the Series 2006-1 notes," said Thompson.

    The Series 2010-2 notes have not been, and will not be, registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release is neither an offer to sell nor a solicitation of an offer to buy any of the Series 2010-2 notes and shall not constitute an offer, solicitation or sale in any jurisdiction in which, or to any person to whom, such offer, solicitation or sale is unlawful.

    About Dollar Thrifty Automotive Group, Inc.

    Dollar Thrifty Automotive Group, Inc. is headquartered in Tulsa, Oklahoma. Driven by the mission "Value Every Time," the Company's brands, Dollar Rent A Car and Thrifty Car Rental, serve value-conscious travelers in over 80 countries. Dollar and Thrifty have over 600 corporate and franchised locations in the United States and Canada, operating in virtually all of the top U.S. and Canadian airport markets. The Company's approximately 6,000 employees are located mainly in North America, but global service capabilities exist through an expanding international franchise network. For additional information, visit http://www.dtag.com/ or the brand sites at http://www.dollar.com/ and http://www.thrifty.com/.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains "forward-looking statements" about our expectations, plans and performance. These statements use such words as "may," "will," "expect," "believe," "intend," "should," "could," "anticipate," "estimate," "forecast," "project," "plan" and similar expressions. These statements do not guarantee future performance and Dollar Thrifty Automotive Group, Inc. assumes no obligation to update them. Risks and uncertainties that could materially affect future results include:

    -- the impact of our pending acquisition by Hertz Global Holdings, Inc. or developments relating to the proposed transaction, including, among other things, diversion of management's attention from day-to-day operations, a loss of key personnel, disruption of our operations, an inability to obtain regulatory and stockholder approvals on the terms and schedule contemplated, and the impact of pending or future litigation relating to the proposed transaction; -- the impact of persistent pricing and demand pressures, particularly in light of the continuing volatility in the global financial and credit markets and concerns about global economic prospects and the timing and strength of a recovery, and whether consumer confidence and spending levels will continue to improve; -- whether ongoing governmental and regulatory initiatives in the United States and elsewhere to stimulate economic growth will be successful; -- the impact of pricing and other actions by competitors, particularly as they increase fleet sizes in anticipation of seasonal activity; -- our ability to manage our fleet mix to match demand and meet our target for vehicle depreciation costs, particularly in light of the significant increase in the level of risk vehicles (i.e., those vehicles not acquired through a guaranteed residual value program) in our fleet and our exposure to the used vehicle market; -- the cost and other terms of acquiring and disposing of automobiles and the impact of conditions in the used vehicle market on our ability to reduce our fleet capacity as and when projected by our plans; -- whether efforts to revitalize the U.S. automotive industry are successful, particularly in light of our dependence on vehicle supply from U.S. automotive manufacturers; -- the effectiveness of actions we take to manage costs and liquidity and whether further reductions in the scope of our operations will be necessary in light of the economic environment; -- our ability to obtain cost-effective financing as needed (including replacement of asset backed notes and other indebtedness as it comes due) without unduly restricting operational flexibility; -- our ability to comply with financial covenants or to obtain necessary amendments or waivers, and the impact of the terms of any required amendments or waivers, such as potential reductions in lender commitments; -- our ability to manage the consequences under our financing agreements of an event of bankruptcy with respect to any of the monoline insurers that provide credit support for our asset backed financing structures, including our ability to obtain any necessary waivers or consents with respect to recent developments involving Ambac; -- the potential for significant cash tax payments in 2010 as a result of the reduction in our fleet size and the resulting impact of our inability to defer gains on the disposition of our vehicles under our like-kind exchange program; -- airline travel patterns, including disruptions or reductions in air travel resulting from airline bankruptcies, industry consolidation, capacity reductions and pricing actions or other events; -- local market conditions where we and our franchisees do business, including whether franchisees will continue to have access to capital as needed; -- volatility in gasoline prices; -- access to reservation distribution channels; -- disruptions in the operation or development of information and communication systems that we rely on, including those relating to methods of payment; -- the cost of regulatory compliance, costs and other effects of potential future initiatives, including those directed at climate change and its effects, and the costs and outcome of pending litigation; and -- the impact of natural catastrophes and terrorism.

    Forward-looking statements should be considered in light of information in this press release and other filings we make with the Securities and Exchange Commission.

    Photo: http://www.newscom.com/cgi-bin/prnh/20020412/DTGLOGO
    AP Archive: http://photoarchive.ap.org/
    http://photos.prnewswire.com/prnh/20020412/DTGLOGO
    PRN Photo Desk, photodesk@prnewswire.com Dollar Thrifty Automotive Group, Inc.

    CONTACT: Financial, H. Clifford Buster III, Chief Financial Officer,
    +1-918-669-3277, or investors, Kindra Marts, Director - Investor Relations,
    +1-918-669-2119, kindra.marts@dtag.com, both of Dollar Thrifty Automotive
    Group, Inc.

    Web Site: http://www.dtag.com/
    http://www.dollar.com/
    http://www.thrifty.com/




    Chemspec International Limited Files 2009 Annual Report on Form 20-F

    SHANGHAI, June 18 /PRNewswire-Asia-FirstCall/ -- Chemspec International Limited ("Chemspec" or the "Company"), a leading China-based contract manufacturer of highly-engineered specialty chemicals, today announced that it filed its annual report on Form 20-F for the year ended December 31, 2009 with the Securities and Exchange Commission on June 17, 2010. The annual report can be accessed on Chemspec's website at http://www.chemspec.com.cn/ under the investor relations section. The annual report is also available on the website of the U.S. Securities and Exchange Commission at http://www.sec.gov/. Chemspec will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements for the year ended December 31, 2009, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Chemspec International Ltd., No.200, Wu Wei Road, Shanghai 200331, People's Republic of China.

    Safe Harbor Statements

    This announcement contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in Chemspec's filings with the U.S. Securities and Exchange Commission, including its registration statement on Form F-1, as amended from time to time. Chemspec does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    About Chemspec

    Chemspec is a leading China-based contract manufacturer of highly engineered specialty chemicals and the largest manufacturer of fluorinated specialty chemicals in China based on sales. In manufacturing specialty chemicals, Chemspec also provides process design and process development services, which enable efficient and rapid production of specialty chemicals that are incorporated into the products of Chemspec's end users. Chemspec's customers and end users include electronics, pharmaceutical and agrochemical companies. For more information, please visit http://www.chemspec.com.cn/ .

    For further information, please contact: Chemspec International Ltd. In Shanghai Carol Fang Tel: +86-21-6363-8108 Email: ir@chemspec.com.cn Christensen In New York Kathy Li Tel: +1-212-618-1978 Email: kli@christensenir.com In Hong Kong Tip Fleming Tel: +852-9212-0684 Email: tfleming@christensenir.com

    Chemspec International Limited

    CONTACT: Chemspec International Ltd., In Shanghai, Carol Fang,
    +86-21-6363-8108, or ir@chemspec.com.cn; or Christensen, In New York, Kathy Li,
    +1-212-618-1978, or kli@christensenir.com; or In Hong Kong, Tip Fleming,
    +852-9212-0684, or tfleming@christensenir.com

    Web site: http://www.chemspec.com.cn/




    China Unicom Announces Filing of Form 20-F with SEC

    HONG KONG, June 18 /PRNewswire-Asia/ -- China Unicom (Hong Kong) Limited (HKSE: 0762; NYSE: CHU) ("the Company") today announced that the Company has filed with the United States Securities and Exchange Commission (the "SEC") its Annual Report on Form 20-F for the year ended December 31, 2009 (the "2009 20-F"). The 2009 20-F is available at the SEC's website at http://www.sec.gov/ and the Company's website at http://www.chinaunicom.com.hk/en/investor/ir_report.html .

    (Logo: http://www.prnasia.com/sa/2009/09/04/200909041651.jpg )

    Hard copies of the Company's complete audited financial statements may be obtained upon request, free of charge, by contacting:

    Mr. Sydney Zhang and Ms. Joanna Rui, Investor Relations Department Tel: +852 2126 2018 Fax: +852 2126 2016 Email: IR@chinaunicom.com.hk Address: 75/F, The Center, 99 Queen's Road Central, Hong Kong.

    At present, the Company is engaged in GSM and WCDMA cellular business in 31 provinces, municipalities and autonomous regions in China, the provision of fixed-line voice, broadband and other Internet-related services, information and communications technology services, business and data communications services, and other related telecommunication value-added businesses.

    For media enquiries, please contact: Dr. Sophia Tso, China Unicom (Hong Kong) Limited Tel: +852-2126-2018 Fax: +852-2126-2016 Email: media@chinaunicom.com.hk

    China Unicom (Hong Kong) Limited

    CONTACT: Dr. Sophia Tso of China Unicom (Hong Kong) Limited,
    +852-2126-2018, +852-2126-2016, media@chinaunicom.com.hk

    Web site: http://www.chinaunicom.com.hk/en/investor/ir_report.html
    http://www.sec.gov/




    Logo Announces Winners for This Year's 'NewNowNext Awards''Glee's' Lea Michele, Johnny Weir, Jesus Luz and 'Burlesque' Among Winners Revealed on Last Night's Telecast Paula Abdul Received the Honorary 'Always Next, Forever Now Icon' Award

    NEW YORK, June 18 /PRNewswire/ -- Logo's third annual "NewNowNext Awards" aired last night on Logo revealing this year's winners honoring the next "big things" in TV, music, film, print and new media long before they hit the mainstream. Join the conversation now on NewNowNext.com for behind-the-scenes photos, videos and content that were too hot for television.

    Filmed at hot spot Edison in downtown Los Angeles, co-hosts Niecy Nash ("Dancing with the Stars," "The Insider," "Clean House," "RENO 911!") and Cheyenne Jackson ("30 Rock") reigned over the festivities that included musical performances by Little Boots, Agnes, Shontelle and Dan Black.

    This year's show featured appearances by Paula Abdul, Mena Suvari ("American Beauty"), Kelly Osbourne, Peter Gallagher, Ryan McPartlin ("Chuck"), Johnny Weir ("Be Good Johnny Weir"), Aisha Tyler ("Archer"), Kristin Cavallari ("The Hills"), RuPaul ("RuPaul's Drag Race"), Snooki and Mike "The Situation" Sorrentino ("Jersey Shore"), Janice Dickinson ("The Janice Dickinson Modeling Agency"), Perez Hilton, Alec Mapa, Candis Cayne ("Nip/Tuck"), Lolene (Capital Recording Artist) and Ross Mathews ("The Tonight Show with Jay Leno"). For a full list of categories and nominees, go to NewNowNext.com. Special appearances for the evening included: Kylie Minogue, on-camera DJ Jesus Luz, the Queens of "RuPaul's Drag Race" and Jessica & Hunter.

    "NewNowNext Awards" is Executive Produced by Christopher Willey and Dave Mace for Logo. Michael Dempsey of Dempsey Productions serves as Executive Producer and Director.

    Winners For The 3rd Annual "NewNowNext Awards" 2010: Brink of Fame: Actor -- Morena Baccarin ("V", ABC) -- Liam Hemsworth (The Last Song) -- Mark Indelicato ("Ugly Betty", ABC) -- Lea Michele ("Glee", FOX) (WINNER) -- Alexander Skarsgard ("True Blood", HBO) -- Paul Wesley ("The Vampire Diaries", CW) OMFG Internet Award -- Chatroulette (chatroulette.com) -- Jessica & Hunter (http://bit.ly/dkzQ64) -- Lesbians Who Look Like Justin Bieber (http://lesbianswholooklikejustinbieber.tumblr.com/) (WINNER) -- shitmydadsays on Twitter (twitter.com/shitmydadsays) -- Very Mary-Kate (verymarykate.com) Best Show You're Not Watching -- "Archer" (FX) (WINNER) -- "Kirstie Alley's Big Life" (A&E) -- "Let's Talk About Pep" (VH1) -- "Nurse Jackie" (Showtime) -- "United States of Tara" (Showtime) Best New Indulgence -- "Hoarders" (A&E) -- "Jersey Shore" (MTV) -- Ke$ha -- "Spartacus: Blood and Sand" (Starz) -- The Split, "RuPaul's Drag Race" (Logo) (WINNER) Most Addictive Reality Star -- Jujubee, "RuPaul's Drag Race" (Logo) -- Khloe Kardashian, "Keeping Up with the Kardashians" (E!) -- Andrew Mukamal, "Kell on Earth" (Bravo) -- Snooki, "Jersey Shore" (MTV) -- Johnny Weir, "Be Good Johnny Weir" (Sundance) (WINNER) Cause You're Hot -- Matthew Bomer ("White Collar", USA) -- Scott Fujita (Linebacker, Cleveland Browns) -- Kellan Lutz (The Twilight Saga) -- Jesus Luz (WINNER) -- Zoe Saldana (Avatar) -- Betty White (The Golden Girls) Best Future Feature -- Burlesque (Screen Gems) (WINNER) -- Eat, Pray, Love (Sony) -- Harry Potter and the Deathly Hallows (Warner Brothers) -- The Kids Are All Right (Focus) -- Salt (Sony) Brink of Fame: Music Artist -- Agnes (WINNER) -- La Roux -- Little Boots -- Passion Pit -- The xx -- VV Brown Brink of Fame: Comic -- Aziz Ansari ("Parks and Recreation") -- Michelle Collins ("Best Week Ever") (WINNER) -- Liz Feldman -- Maulik Pancholy ("30 Rock") -- Amy Phillips About Logo:

    Logo is the world's leading ad-supported cable, satellite, online, mobile and digital entertainment network from MTV Networks, a unit of Viacom for gays and lesbians, their families and friends. Launched in 2005, Logo's cable channel is in more than 46 million homes across the United States and is complemented by a federation of online properties, including LogoTV.com, TripOutGayTravel.com, AfterEllen.com, AfterElton.com, 365Gay.com, DowneLink.com and NewNowNext.com. Logo's content is distributed across all leading download-to-own, streaming and mobile services. The most influential brand for the most influential audience, Logo provides a mix of original and acquired entertainment as well as news, social networking and community building that are authentic, smart, fun, entertaining, and inclusive. Logo joins MTV Networks' roster of popular and highly targeted brands which include MTV, Comedy Central, VH1 and Spike TV.

    Contacts: Jason Shumaker 212-846-7325 Jason.Shumaker@mtvn.com Michael Barrett 212-654-3060 Michael.Barrett@logostaff.com Jake Slane 310-752-8370 Jake.Slane@vh1.com

    Logo

    CONTACT: Jason Shumaker, +1-212-846-7325, Jason.Shumaker@mtvn.com, or
    Michael Barrett, +1-212-654-3060, Michael.Barrett@logostaff.com, or Jake
    Slane, +1-310-752-8370, Jake.Slane@vh1.com

    Web Site: http://www.logotv.com/
    http://www.newnownext.com/




    STMicroelectronics and Tsinghua University Announce Long-Term Strategic R&D Partnership

    SHENZHEN, China, June 18 /PRNewswire-FirstCall/ -- STMicroelectronics and Tsinghua University, Shenzhen Graduate School, have reached a long-term strategic research partnership agreement. This agreement is the second phase of a collaboration that began in 2002 with the setup of a joint ASIC (Application Specific Integrated Circuit) research center.

    STMicroelectronics is to provide the University with digital multimedia and advanced analog chips, expert support and advanced design tools, and jointly cooperate on applications engineering projects assigned by ST to the University. Under the terms of the strategic partnership, ST will also donate RMB 1.0 million to the Graduate School each year for five years, with an overall assessment of research efforts conducted each year.

    The Graduate School and the Electronic Engineering department of Tsinghua University will staff the long-term partnership with talent, including graduates and technical staff that have important know-how for the market in China, such as local standards and technical specifications in various application fields.

    "This partnership provides a great opportunity for Tsinghua University to develop IP blocks and ICs that meet market demand, raising our design and innovation skills to a new level," said Prof. Kang Feiyu, Vice-president of Tsinghua University Graduate School, Shenzhen, "Leveraging our expertise, talents and management to extend the cooperation between us, the partnership is intended for applications that will be commercialized within five years, which is ideal for Chinese designers to sharpen their skills very quickly."

    Francois Guibert, Executive Vice President and President, Greater China and South Asia region, STMicroelectronics welcomed this deepening collaboration. "ST has had a strong technical presence in China for many years. This presence has included manufacturing, IC design and applications teams. The collaboration with Tsinghua will enhance ST's capabilities to tailor our IC solutions to the local market needs." Mr. Guibert added, "This partnership with Tsinghua University will contribute to maintaining and further strengthening our relationship with industry leaders in the most dynamic and fastest growing market in the world."

    The collaboration with Tsinghua is part of an R&D network established by STMicroelectronics with many world leading universities, research institutes, customers and suppliers in Europe, Asia and America. It aims to bring a dramatic increase in the availability of advanced IP blocks and chips designed in China.

    About Tsinghua University Graduate School, Shenzhen

    Founded in 2001, Tsinghua University Graduate School, Shenzhen is the only campus site of Tsinghua University, beyond its location in Beijing. The mission of the Graduate School is to serve the local economy by developing and training world-class talent, while also seeking collaboration with top-tier businesses in the Shenzhen area.

    About STMicroelectronics

    STMicroelectronics is a global leader serving customers across the spectrum of electronics applications with innovative semiconductor solutions. ST aims to be the undisputed leader in multimedia convergence and power applications leveraging its vast array of technologies, design expertise and combination of intellectual property portfolio, strategic partnerships and manufacturing strength. In 2009, the Company's net revenues were $8.51 billion. Further information on ST can be found at http://www.st.com/.

    STMicroelectronics

    CONTACT: Michael Markowitz of STMicroelectronics, +1-212-821-8959,
    michael.markowitz@st.com, or Tsinghua University: Ms. Ma Li,
    +86-755-2603-6337, mal@sz.tsinghua.edu.cn

    Web Site: http://www.st.com/




    National Technical Systems Declares Special Dividend

    CALABASAS, Calif., June 18 /PRNewswire-FirstCall/ -- On June 17, 2010, the Board of Directors of National Technical Systems, Inc. (NTS), a leading provider of engineering services, declared a special cash dividend of $0.07 per common share payable on July 19, 2010, to shareholders of record on July 6, 2010.

    Although the Company does not currently have a policy of issuing regular dividends or special dividends and the Board does not contemplate a change in that policy, the Board may consider special dividends from time-to-time in the future in light of then existing conditions, including earnings, cash condition and capital requirements. Notwithstanding the foregoing, no assurance is given that there will be any special dividends declared in the foreseeable future.

    About National Technical Systems

    National Technical Systems, Inc. is a leading provider of engineering and testing services to the defense, aerospace, telecommunications, automotive and high technology markets. Through a world-wide network of resources, NTS provides full life-cycle product integrity support, offering world class design engineering, compliance, testing, certification, quality registration and program management. For additional information about NTS, visit our website at http://www.ntscorp.com/ or call 800-270-2516.

    Forward Looking Statements

    The statements in this press release that relate to future plans, events or performance, are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties pertaining to customer orders, including the possibility of contract cancellations, demand for services and products, development of markets for the companies' services and products and other risks identified in the companies' SEC filings. Actual results, events and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The companies undertake no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding National Technical Systems' business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.

    Contact: Allen & Caron National Technical Systems Jill Bertotti (investors) Aaron Cohen, Vice Chairman (corporate) Jill@allencaron.com aaron.cohen@ntscorp.com Len Hall (media) Raffy Lorentzian, Sr. Vice President, CFO len@allencaron.com raffy.lorentzian@ntscorp.com (949) 474-4300 (818) 591-0776

    Photo: http://www.newscom.com/cgi-bin/prnh/20091001/NTSLOGO
    http://photoarchive.ap.org/
    PRN Photo Desk, photodesk@prnewswire.com
    http://photos.prnewswire.com/prnh/20091001/NTSLOGO National Technical Systems, Inc.

    CONTACT: investors, Jill Bertotti, Jill@allencaron.com, or media, Len
    Hall, len@allencaron.com, both of Allen & Caron, +1-949-474-4300, for National
    Technical Systems; or corporate, Aaron Cohen, Vice Chairman,
    aaron.cohen@ntscorp.com, or Raffy Lorentzian, Sr. Vice President, CFO,
    raffy.lorentzian@ntscorp.com, both of National Technical Systems,
    +1-818-591-0776

    Web Site: http://www.ntscorp.com/




    CNOOC Ltd. Completes Acquisition of Stake in Block 15/34

    HONG KONG, June 18 /PRNewswire-Asia/ -- CNOOC Limited (the "Company" or "CNOOC Ltd.", NYSE: CEO, HKEx: 00883) announced today that the Company has completed its acquisition of 24.5% participation interests in Block 15/34 from Devon Energy Corporation ("Devon") for a total consideration of US$515 million. The transaction was signed on April 30, 2010.

    (Logo: http://www.prnasia.com/xprn/sa/200701301659.jpg )

    CNOOC Ltd. acts as the Operator in Block 15/34. Currently gross production from the block is 49,000 barrels of oil per day.

    After this transfer, CNOOC Ltd. will increase its stake to 75.5% in Block 15/34.

    Notes to Editors:

    More information about the Company is available at http://www.cnoocltd.com/.

    This press release includes "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, including statements regarding expected future events, business prospectus or financial results. The words "believe", "intend", "expect", "anticipate", "project", "estimate", "plan", "predict" and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by us that we believe are reasonable under the circumstances. However, whether actual results and developments will meet our expectations and predictions depend on a number of risks and uncertainties which could cause our actual results, performance and financial condition to differ materially from our expectations. For a description of these and other risks and uncertainties, please see the documents we file from time to time with the United States Securities and Exchange Commission, including our 2009 Annual Report on Form 20-F filed on April 23, 2010.

    For further enquiries, please contact: Mr. Jiang Yongzhi Joint Company Secretary and General Manager of Investor Relations Department CNOOC Limited Tel: +86-10-8452-1731 Fax: +86-10-8452-1441 Email: jiangyzh2@cnooc.com.cn Ms. Sharon Fung Ketchum Newscan Public Relations Ltd Tel: +852-3141-8082 Fax: +852-2510-8199 Email: sharon.fung@knprhk.com

    CNOOC Limited

    CONTACT: Mr. Jiang Yongzhi, Joint Company Secretary and General Manager
    of Investor Relations Department of CNOOC Limited, +86-10-8452-1731, or fax,
    +86-10-8452-1441, or jiangyzh2@cnooc.com.cn; or Ms. Sharon Fung at Ketchum
    Newscan Public Relations Ltd, +852-3141-8082, or fax, +852-2510-8199, or
    sharon.fung@knprhk.com

    Web Site: http://www.cnoocltd.com/
    http://www.prnasia.com/sa/200701301659.jpg

    page 1     page 2     page 3     page 4     page 5    

    News archive of August 2014
    1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31 



    News Archives of June 2010
    1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31  

    News Archives other dates
        2014:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2013:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2012:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2011:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2010:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2009:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2008:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2007:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2006:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec